Pompe	NN	Pompe
disease	NN	disease
is	VBZ	be
a	DT	a
lysosomal	JJ	lysosomal
storage	NN	storage
disorder	NN	disorder
caused	VVN	cause
by	IN	by
a	DT	a
deficiency	NN	deficiency
of	IN	of
the	DT	the
enzyme	NN	enzyme
acid	NN	acid
alpha-glucosidase	NN	alpha-glucosidase
.	SENT	.
Patients	NNS	patient
have	VHP	have
skeletal	JJ	skeletal
muscle	NN	muscle
and	CC	and
respiratory	JJ	respiratory
weakness	NN	weakness
with	IN	with
or	CC	or
without	IN	without
cardiomyopathy	NN	cardiomyopathy
.	SENT	.
The	DT	the
objective	NN	objective
of	IN	of
our	PP$	our
review	NN	review
was	VBD	be
to	TO	to
systematically	RB	systematically
evaluate	VV	evaluate
the	DT	the
quality	NN	quality
of	IN	of
evidence	NN	evidence
from	IN	from
the	DT	the
literature	NN	literature
to	TO	to
formulate	VV	formulate
evidence-based	JJ	evidence-based
guidelines	NNS	guideline
for	IN	for
the	DT	the
diagnosis	NN	diagnosis
and	CC	and
management	NN	management
of	IN	of
patients	NNS	patient
with	IN	with
Pompe	NP	Pompe
disease	NN	disease
.	SENT	.
The	DT	the
literature	NN	literature
review	NN	review
was	VBD	be
conducted	VVN	conduct
using	VVG	use
published	VVN	publish
literature	NN	literature
,	,	,
clinical	JJ	clinical
trials	NNS	trial
,	,	,
cohort	NN	cohort
studies	NNS	study
and	CC	and
systematic	JJ	systematic
reviews	NNS	review
.	SENT	.
Cardinal	NP	Cardinal
treatment	NN	treatment
decisions	NNS	decision
produced	VVD	produce
seven	CD	seven
management	NN	management
guidelines	NNS	guideline
and	CC	and
were	VBD	be
assigned	VVN	assign
a	DT	a
GRADE	NP	Grade
classification	NN	classification
based	VVN	base
on	IN	on
the	DT	the
quality	NN	quality
of	IN	of
evidence	NN	evidence
in	IN	in
the	DT	the
published	VVN	publish
literature	NN	literature
.	SENT	.
In	IN	in
addition	NN	addition
,	,	,
six	CD	six
recommendations	NNS	recommendation
were	VBD	be
made	VVN	make
based	VVN	base
on	IN	on
best	JJS	good
clinical	JJ	clinical
practices	NNS	practice
but	CC	but
with	IN	with
insufficient	JJ	insufficient
data	NNS	datum
to	TO	to
form	VV	form
a	DT	a
guideline	NN	guideline
.	SENT	.
Studying	VVG	study
outcomes	NNS	outcome
in	IN	in
rare	JJ	rare
diseases	NNS	disease
is	VBZ	be
challenging	VVG	challenge
due	JJ	due
to	TO	to
the	DT	the
small	JJ	small
number	NN	number
of	IN	of
patients	NNS	patient
,	,	,
but	CC	but
this	DT	this
is	VBZ	be
in	RB	in
particular	JJ	particular
the	DT	the
reason	NN	reason
why	WRB	why
we	PP	we
believe	VVP	believe
that	IN/that	that
informed	JJ	informed
treatment	NN	treatment
decisions	NNS	decision
need	VVP	need
to	TO	to
consider	VV	consider
the	DT	the
quality	NN	quality
of	IN	of
the	DT	the
evidence	NN	evidence


Pompe	NN	Pompe
disease	NN	disease
is	VBZ	be
a	DT	a
fatal	JJ	fatal
genetic	JJ	genetic
muscle	NN	muscle
disorder	NN	disorder
caused	VVN	cause
by	IN	by
a	DT	a
deficiency	NN	deficiency
of	IN	of
acid	JJ	acid
α-glucosidase	NN	α-glucosidase
(	(	(
GAA	NP	GAA
)	)	)
,	,	,
a	DT	a
glycogen-degrading	JJ	glycogen-degrading
lysosomal	JJ	lysosomal
enzyme	NN	enzyme
.	SENT	.
In	IN	in
this	DT	this
study	NN	study
,	,	,
the	DT	the
human	JJ	human
GAA	NP	GAA
cDNA	NN	cDNA
gene	NN	gene
was	VBD	be
synthesized	VVN	synthesize
from	IN	from
human	JJ	human
placenta	NN	placenta
cells	NNS	cell
and	CC	and
cloned	VVN	clon
into	IN	into
a	DT	a
plant	NN	plant
expression	NN	expression
vector	NN	vector
under	IN	under
the	DT	the
control	NN	control
of	IN	of
the	DT	the
rice	NN	rice
α-amylase	NN	α-amylase
3D	JJ	3D
(	(	(
RAmy3D	NP	RAmy3D
)	)	)
promoter	NN	promoter
.	SENT	.
The	DT	the
plant	NN	plant
expression	NN	expression
vector	NN	vector
was	VBD	be
introduced	VVN	introduce
into	IN	into
rice	NN	rice
calli	NNS	calli
(	(	(
Oryza	NP	Oryza
sativa	NP	sativa
L.	NP	L.
cv	NN	cv
.	SENT	.
Dongjin	NP	Dongjin
)	)	)
mediated	VVD	mediate
by	IN	by
Agrobacterium	NN	Agrobacterium
tumefaciens	NNS	tumefaciens
.	SENT	.
Genomic	NP	Genomic
DNA	NP	DNA
PCR	NP	PCR
and	CC	and
Northern	NP	Northern
blot	NN	blot
analysis	NN	analysis
were	VBD	be
used	VVN	use
to	TO	to
determine	VV	determine
the	DT	the
integration	NN	integration
and	CC	and
mRNA	NN	mRNA
expression	NN	expression
of	IN	of
the	DT	the
hGAA	NN	hGAA
gene	NN	gene
in	IN	in
the	DT	the
putative	JJ	putative
transgenic	JJ	transgenic
rice	NN	rice
cells	NNS	cell
.	SENT	.
SDS-PAGE	NP	SDS-PAGE
and	CC	and
Western	NP	Western
blot	NN	blot
analysis	NN	analysis
showed	VVD	show
that	IN/that	that
the	DT	the
glycosylated	JJ	glycosylated
precursor	NN	precursor
recombinant	JJ	recombinant
hGAA	NN	hGAA
had	VHD	have
a	DT	a
molecular	JJ	molecular
mass	NN	mass
of	IN	of
110kDa	NP	110kDa
due	JJ	due
to	TO	to
the	DT	the
presence	NN	presence
of	IN	of
seven	CD	seven
N-glycosylation	NN	N-glycosylation
sites	NNS	site
.	SENT	.
The	DT	the
accumulation	NN	accumulation
of	IN	of
hGAA	NN	hGAA
protein	NN	protein
in	IN	in
the	DT	the
culture	NN	culture
medium	NN	medium
was	VBD	be
approximately	RB	approximately
37mg/L	JJ	37mg/L
after	IN	after
11	CD	@card@
days	NNS	day
of	IN	of
culturing	VVG	culture
in	IN	in
a	DT	a
sugar	NN	sugar
depletion	NN	depletion
medium	NN	medium
.	SENT	.
The	DT	the
His	PP$	his
tagged-hGAA	NN	tagged-hGAA
protein	NN	protein
was	VBD	be
purified	VVN	purify
using	VVG	use
an	DT	an
Ni-NTA	NP	Ni-NTA
column	NN	column
and	CC	and
confirmed	VVD	confirm
as	IN	as
the	DT	the
precursor	NN	precursor
form	NN	form
of	IN	of
hGAA	NN	hGAA
without	IN	without
the	DT	the
signal	NN	signal
peptide	NN	peptide
encoded	VVN	encode
by	IN	by
the	DT	the
cDNA	NN	cDNA
on	IN	on
the	DT	the
N-terminal	JJ	N-terminal
amino	NN	amino
acid	NN	acid
sequence	NN	sequence
.	SENT	.
The	DT	the
acid	JJ	acid
alpha-glucosidase	NN	alpha-glucosidase
activity	NN	activity
of	IN	of
hGAA	NN	hGAA
produced	VVN	produce
in	IN	in
transgenic	JJ	transgenic
rice	NN	rice
cells	NNS	cell
gave	VVD	give
results	NNS	result
similar	JJ	similar
to	TO	to
those	DT	those
of	IN	of
the	DT	the
enzyme	NN	enzyme
produced	VVN	produce
by	IN	by
CHO	NP	Cho
cells	NNS	cell
.	SENT	.


Late-onset	NN	late-onset
Pompe	NN	Pompe
disease	NN	disease
(	(	(
LOPD	NP	LOPD
)	)	)
is	VBZ	be
a	DT	a
metabolic	JJ	metabolic
myopathy	NN	myopathy
caused	VVN	cause
by	IN	by
mutations	NNS	mutation
in	IN	in
GAA	NP	GAA
and	CC	and
characterized	VVN	characterize
by	IN	by
proximal	JJ	proximal
muscle	NN	muscle
weakness	NN	weakness
and	CC	and
respiratory	JJ	respiratory
insufficiency	NN	insufficiency
.	SENT	.
There	EX	There
is	VBZ	be
evidence	NN	evidence
from	IN	from
clinical	JJ	clinical
studies	NNS	study
that	IN/that	that
enzyme	NN	enzyme
replacement	NN	replacement
therapy	NN	therapy
(	(	(
ERT	NN	ERT
)	)	)
with	IN	with
human	JJ	human
recombinant	JJ	recombinant
alpha-glucosidase	NN	alpha-glucosidase
improves	VVZ	improve
motor	NN	motor
performance	NN	performance
and	CC	and
respiratory	JJ	respiratory
function	NN	function
in	IN	in
LOPD.We	NP	LOPD.We
analyzed	VVD	analyze
quantitative	JJ	quantitative
muscle	NN	muscle
MRI	NP	MRI
data	NNS	datum
of	IN	of
lower	JJR	low
limbs	NNS	limb
to	TO	to
evaluate	VV	evaluate
the	DT	the
effects	NNS	effect
of	IN	of
long-term	JJ	long-term
ERT	NN	ERT
on	IN	on
muscle	NN	muscle
parameters.Three	NN	parameters.Three
symptomatic	JJ	symptomatic
LOPD	NP	LOPD
patients	NNS	patient
who	WP	who
received	VVD	receive
ERT	NN	ERT
for	IN	for
five	CD	five
years	NNS	year
and	CC	and
four	CD	four
untreated	JJ	untreated
presymptomatic	JJ	presymptomatic
LOPD	NN	LOPD
patients	NNS	patient
were	VBD	be
included	VVN	include
in	IN	in
the	DT	the
study	NN	study
.	SENT	.
T1-weighted	NP	T1-weighted
MRI	NP	MRI
images	NNS	image
were	VBD	be
used	VVN	use
to	TO	to
determine	VV	determine
volumes	NNS	volume
of	IN	of
thigh	NN	thigh
and	CC	and
lower	JJR	low
leg	NN	leg
muscles	NNS	muscle
.	SENT	.
In	IN	in
addition	NN	addition
,	,	,
mean	VVP	mean
gray	JJ	gray
values	NNS	value
of	IN	of
eight	CD	eight
individual	JJ	individual
thigh	NN	thigh
muscles	NNS	muscle
were	VBD	be
calculated	VVN	calculate
to	TO	to
assess	VV	assess
the	DT	the
degree	NN	degree
of	IN	of
lipomatous	JJ	lipomatous
muscle	NN	muscle
alterations.We	NP	alterations.We
detected	VVD	detect
a	DT	a
decrease	NN	decrease
in	IN	in
thigh	NN	thigh
muscle	NN	muscle
volume	NN	volume
of	IN	of
6.7	CD	@card@
%	NN	%
(	(	(
p	NN	p
<	SYM	<
0.001	CD	@card@
)	)	)
and	CC	and
an	DT	an
increase	NN	increase
in	IN	in
lower	JJR	low
leg	NN	leg
muscle	NN	muscle
volume	NN	volume
of	IN	of
8.2	CD	@card@
%	NN	%
(	(	(
p	NN	p
=	SYM	=
0.049	CD	@card@
)	)	)
after	IN	after
five	CD	five
years	NNS	year
of	IN	of
ERT	NN	ERT
.	SENT	.
Analysis	NN	analysis
of	IN	of
individual	JJ	individual
thigh	NN	thigh
muscles	NNS	muscle
revealed	VVD	reveal
a	DT	a
positive	JJ	positive
correlation	NN	correlation
between	IN	between
the	DT	the
degree	NN	degree
of	IN	of
lipomatous	JJ	lipomatous
muscle	NN	muscle
alterations	NNS	alteration
at	IN	at
baseline	NN	baseline
and	CC	and
the	DT	the
increase	NN	increase
of	IN	of
gray	JJ	gray
values	NNS	value
after	IN	after
five	CD	five
years	NNS	year
of	IN	of
ERT	NN	ERT
(	(	(
R(2	NP	R(2
)	)	)
=	SYM	=
0.68	CD	@card@
,	,	,
p	NN	p
<	SYM	<
0.001	CD	@card@
)	)	)
.	SENT	.
Muscle	NN	muscle
imaging	NN	imaging
in	IN	in
presymptomatic	JJ	presymptomatic
patients	NNS	patient
showed	VVD	show
in	IN	in
one	CD	one
case	NN	case
pronounced	VVD	pronounce
lipomatous	JJ	lipomatous
alteration	NN	alteration
of	IN	of
the	DT	the
adductor	NN	adductor
magnus	NN	magnus
muscle	NN	muscle
and	CC	and
mild	JJ	mild
to	TO	to
moderate	JJ	moderate
changes	NNS	change
in	IN	in
further	JJR	further
thigh	NN	thigh
muscles.The	NN	muscles.The
results	NNS	result
demonstrate	VVP	demonstrate
that	IN/that	that
fatty	JJ	fatty
muscle	NN	muscle
degeneration	NN	degeneration
can	MD	can
occur	VV	occur
before	IN	before
clinical	JJ	clinical
manifestation	NN	manifestation
of	IN	of
muscle	NN	muscle
weakness	NN	weakness
and	CC	and
suggest	VVP	suggest
that	IN/that	that
mildly	RB	mildly
affected	VVN	affect
muscles	NNS	muscle
may	MD	may
respond	VV	respond
better	RBR	well
to	TO	to
ERT	NN	ERT
treatment	NN	treatment
than	IN	than
severely	RB	severely
involved	VVN	involve
muscles	NNS	muscle
.	SENT	.
If	IN	if
these	DT	these
findings	NNS	finding
can	MD	can
be	VB	be
validated	VVN	validate
by	IN	by
further	JJR	further
studies	NNS	study
,	,	,
it	PP	it
should	MD	should
be	VB	be
discussed	VVN	discuss
if	IN	if
muscle	NN	muscle
alterations	NNS	alteration
detected	VVN	detect
by	IN	by
muscle	NN	muscle
MRI	NP	MRI
may	MD	may
be	VB	be
an	DT	an
objective	JJ	objective
sign	NN	sign
of	IN	of
disease	NN	disease
manifestation	NN	manifestation
justifying	VVG	justify
an	DT	an
early	JJ	early
start	NN	start
of	IN	of
ERT	NN	ERT
in	IN	in
clinically	RB	clinically
asymptomatic	JJ	asymptomatic
patients	NNS	patient
in	IN	in
order	NN	order
to	TO	to
improve	VV	improve
the	DT	the
long-term	JJ	long-term
outcome	NN	outcome
.	SENT	.



Male	JJ	male
infertility	NN	infertility
is	VBZ	be
a	DT	a
multifactorial	JJ	multifactorial
state	NN	state
.	SENT	.
Among	IN	among
other	JJ	other
risk	NN	risk
factors	NNS	factor
,	,	,
drugs	NNS	drug
can	MD	can
adversely	RB	adversely
affect	VV	affect
male	JJ	male
fertility	NN	fertility
and	CC	and
male	JJ	male
sexual	JJ	sexual
function	NN	function
.	SENT	.
In	IN	in
a	DT	a
retrospective	JJ	retrospective
study	NN	study
we	PP	we
aimed	VVD	aim
to	TO	to
analyse	VV	analyse
how	WRB	how
many	DT	many
involuntarily	RB	involuntarily
childless	JJ	childless
men	NNS	man
seeking	VVG	seek
fertility	NN	fertility
evaluation	NN	evaluation
consume	VVP	consume
drugs	NNS	drug
,	,	,
which	WDT	which
drugs	NNS	drug
and	CC	and
if	IN	if
these	DT	these
are	VBP	be
potentially	RB	potentially
affecting	VVG	affect
male	JJ	male
reproductive	JJ	reproductive
function.We	NNS	function.We
retrospectively	RB	retrospectively
identified	VVN	identify
involuntarily	RB	involuntarily
childless	JJ	childless
men	NNS	man
presenting	VVG	present
for	IN	for
fertility	NN	fertility
evaluation	NN	evaluation
at	IN	at
an	DT	an
andrologic	JJ	andrologic
outpatient	NN	outpatient
department	NN	department
from	IN	from
2011	CD	@card@
to	TO	to
2014.	CD	@ord@
Medical	NP	Medical
records	NNS	record
were	VBD	be
searched	VVD	search
for	IN	for
current	JJ	current
drug	NN	drug
use	NN	use
,	,	,
age	NN	age
,	,	,
diseases	NNS	disease
affecting	VVG	affect
male	JJ	male
fertility	NN	fertility
,	,	,
and	CC	and
number	NN	number
and	CC	and
kind	NN	kind
of	IN	of
drugs	NNS	drug
.	SENT	.
Drugs	NNS	drug
were	VBD	be
classified	VVN	classify
according	VVG	accord
to	TO	to
their	PP$	their
Anatomical	NP	Anatomical
Therapeutic	NP	Therapeutic
Chemical	NP	Chemical
code	NN	code
.	SENT	.
Adverse	JJ	adverse
drug	NN	drug
reactions	NNS	reaction
on	IN	on
male	JJ	male
sexual	JJ	sexual
function	NN	function
and	CC	and
fertility	NN	fertility
were	VBD	be
searched	VVN	search
in	IN	in
two	CD	two
independent	JJ	independent
literature	NN	literature
sources.Drug	NN	sources.Drug
use	NN	use
was	VBD	be
documented	VVN	document
for	IN	for
244	CD	@card@
of	IN	of
522	CD	@card@
patients	NNS	patient
(	(	(
46.7	CD	@card@
%	NN	%
)	)	)
.	SENT	.
The	DT	the
patients	NNS	patient
mean	JJ	mean
age	NN	age
was	VBD	be
37.7 	JJ	37.7 
;	:	;
± 	NN	± 
;	:	;
8.7	CD	@card@
;	:	;
the	DT	the
total	JJ	total
number	NN	number
of	IN	of
drug	NN	drug
intakes	NNS	intake
was	VBD	be
554	CD	@card@
(	(	(
mean	VV	mean
2.3 	JJ	2.3 
;	:	;
± 	NN	± 
;	:	;
1.9	CD	@card@
)	)	)
,	,	,
corresponding	JJ	corresponding
to	TO	to
201	CD	@card@
different	JJ	different
drugs	NNS	drug
.	SENT	.
The	DT	the
most	RBS	most
often	RB	often
involved	VVN	involve
Anatomical	NP	Anatomical
Therapeutic	NP	Therapeutic
Chemical	NP	Chemical
groups	NNS	group
were	VBD	be
nervous	JJ	nervous
system	NN	system
(	(	(
N	NP	N
)	)	)
,	,	,
alimentary	JJ	alimentary
tract/metabolism	NN	tract/metabolism
(	(	(
A	NP	A
)	)	)
,	,	,
cardiovascular	JJ	cardiovascular
(	(	(
C	NP	C
)	)	)
,	,	,
and	CC	and
respiratory	JJ	respiratory
system	NN	system
(	(	(
R	NP	R
)	)	)
(	(	(
n 	JJ	n 
;	:	;
= 	NN	= 
;	:	;
277	CD	@card@
;	:	;
50.0	CD	@card@
%	NN	%
)	)	)
.	SENT	.
Fertility	NN	fertility
impairment	NN	impairment
was	VBD	be
reported	VVN	report
for	IN	for
15.9	CD	@card@
%	NN	%
,	,	,
and	CC	and
adverse	JJ	adverse
drug	NN	drug
reactions	NNS	reaction
on	IN	on
male	JJ	male
sexual	JJ	sexual
function	NN	function
were	VBD	be
found	VVN	find
for	IN	for
51.2	CD	@card@
%	NN	%
of	IN	of
all	DT	all
identified	VVN	identify
drugs	NNS	drug
.	SENT	.
Underreporting	VVG	underreport
of	IN	of
consumed	VVN	consume
drugs	NNS	drug
was	VBD	be
likely	JJ	likely
,	,	,
especially	RB	especially
for	IN	for
non-prescription	JJ	non-prescription
drugs.A	NN	drugs.A
high	JJ	high
percentage	NN	percentage
of	IN	of
involuntarily	RB	involuntarily
childless	JJ	childless
men	NNS	man
is	VBZ	be
taking	VVG	take
drugs	NNS	drug
that	WDT	that
can	MD	can
potentially	RB	potentially
influence	VV	influence
male	JJ	male
reproductive	JJ	reproductive
function	NN	function
.	SENT	.
As	IN	as
drug	NN	drug
intake	NN	intake
represents	VVZ	represent
a	DT	a
modifiable	JJ	modifiable
risk	NN	risk
factor	NN	factor
,	,	,
fertility	NN	fertility
evaluation	NN	evaluation
requires	VVZ	require
a	DT	a
comprehensive	JJ	comprehensive
medication	NN	medication
review	NN	review
including	VVG	include
prescription	NN	prescription
and	CC	and
non-prescription	JJ	non-prescription
drugs	NNS	drug
.	SENT	.
Copyright	NN	copyright
©	NN	©
;	:	;
2016	CD	@card@
John	NP	John
Wiley	NP	Wiley
&	CC	&
Sons	NP	Sons
,	,	,
Ltd.	NP	Ltd.



The	DT	the
international	JJ	international
transplant	NN	transplant
community	NN	community
portrays	VVZ	portray
organ	NN	organ
trade	NN	trade
as	IN	as
a	DT	a
growing	JJ	growing
and	CC	and
serious	JJ	serious
crime	NN	crime
involving	VVG	involve
large	JJ	large
numbers	NNS	number
of	IN	of
traveling	VVG	travel
patients	NNS	patient
who	WP	who
purchase	VVP	purchase
organs	NNS	organ
.	SENT	.
We	PP	we
present	VVP	present
a	DT	a
systematic	JJ	systematic
review	NN	review
about	IN	about
the	DT	the
published	VVN	publish
number	NN	number
of	IN	of
patients	NNS	patient
that	WDT	that
purchased	VVD	purchase
organs	NNS	organ
.	SENT	.
With	IN	with
this	DT	this
information	NN	information
we	PP	we
discuss	VVP	discuss
whether	IN	whether
the	DT	the
scientific	JJ	scientific
literature	NN	literature
reflects	VVZ	reflect
a	DT	a
substantial	JJ	substantial
practice	NN	practice
of	IN	of
organ	NN	organ
purchase	NN	purchase
.	SENT	.
Between	IN	between
2000	CD	@card@
and	CC	and
2015	CD	@card@
,	,	,
86	CD	@card@
studies	NNS	study
were	VBD	be
published	VVN	publish
.	SENT	.
Seventy-six	NN	Seventy-six
of	IN	of
these	DT	these
presented	VVN	present
patients	NNS	patient
who	WP	who
traveled	VVD	travel
and	CC	and
42	CD	@card@
stated	VVD	state
that	IN/that	that
the	DT	the
transplants	NNS	transplant
were	VBD	be
commercial	JJ	commercial
.	SENT	.
Only	RB	only
11	CD	@card@
studies	NNS	study
reported	VVD	report
that	IN/that	that
patients	NNS	patient
paid	VVD	pay
and	CC	and
8	CD	8
described	VVN	describe
to	TO	to
what	WP	what
or	CC	or
whom	WP	whom
patients	NNS	patient
paid	VVD	pay
.	SENT	.
In	IN	in
total	NN	total
,	,	,
over	IN	over
a	DT	a
period	NN	period
of	IN	of
42	CD	@card@
years	NNS	year
,	,	,
6002	CD	@card@
patients	NNS	patient
have	VHP	have
been	VBN	be
reported	VVN	report
to	TO	to
travel	VV	travel
for	IN	for
transplantation	NN	transplantation
.	SENT	.
Of	IN	of
these	DT	these
,	,	,
only	RB	only
1238	CD	@card@
were	VBD	be
reported	VVN	report
to	TO	to
have	VH	have
paid	VVN	pay
for	IN	for
their	PP$	their
transplants	NNS	transplant
.	SENT	.
An	DT	an
additional	JJ	additional
unknown	JJ	unknown
number	NN	number
of	IN	of
patients	NNS	patient
paid	VVN	pay
for	IN	for
their	PP$	their
transplants	NNS	transplant
in	IN	in
their	PP$	their
native	JJ	native
countries	NNS	country
.	SENT	.
We	PP	we
conclude	VVP	conclude
that	IN/that	that
the	DT	the
scientific	JJ	scientific
literature	NN	literature
does	VVZ	do
not	RB	not
reflect	VV	reflect
a	DT	a
large	JJ	large
number	NN	number
of	IN	of
patients	NNS	patient
buying	VVG	buy
organs	NNS	organ
.	SENT	.
Organ	NN	organ
purchases	NNS	purchase
were	VBD	be
more	RBR	more
often	RB	often
assumed	VVN	assume
than	IN	than
determined	VVN	determine
.	SENT	.
A	DT	a
reporting	VVG	report
code	NN	code
for	IN	for
transplant	NN	transplant
professionals	NNS	professional
to	TO	to
report	VV	report
organ	NN	organ
trafficking	NN	trafficking
networks	NNS	network
is	VBZ	be
a	DT	a
potential	JJ	potential
strategy	NN	strategy
to	TO	to
collect	VV	collect
and	CC	and
quantify	VV	quantify
cases	NNS	case
.	SENT	.
This	DT	this
article	NN	article
is	VBZ	be
protected	VVN	protect
by	IN	by
copyright	NN	copyright
.	SENT	.
All	DT	all
rights	NNS	right
reserved	VVD	reserve
.	SENT	.



TIt	NN	tit
is	VBZ	be
known	VVN	know
that	IN/that	that
when	WRB	when
symbolizing	VVG	symbolize
a	DT	a
time	NN	time
series	NN	series
into	IN	into
ordinal	JJ	ordinal
patterns	NNS	pattern
using	VVG	use
the	DT	the
Bandt-Pompe	NP	Bandt-Pompe
(	(	(
BP	NP	BP
)	)	)
methodology	NN	methodology
,	,	,
there	EX	there
will	MD	will
be	VB	be
ordinal	JJ	ordinal
patterns	NNS	pattern
called	VVD	call
forbidden	VVN	forbid
patterns	NNS	pattern
that	WDT	that
do	VVP	do
not	RB	not
occur	VV	occur
in	IN	in
a	DT	a
deterministic	JJ	deterministic
series	NN	series
.	SENT	.
The	DT	the
existence	NN	existence
of	IN	of
forbidden	VVN	forbid
patterns	NNS	pattern
can	MD	can
be	VB	be
used	VVN	use
to	TO	to
identify	VV	identify
deterministic	JJ	deterministic
dynamics	NNS	dynamics
.	SENT	.
In	IN	in
this	DT	this
paper	NN	paper
,	,	,
the	DT	the
ability	NN	ability
to	TO	to
use	VV	use
forbidden	VVN	forbid
patterns	NNS	pattern
to	TO	to
detect	VV	detect
determinism	NN	determinism
in	IN	in
irregularly	RB	irregularly
sampled	VVN	sample
time	NN	time
series	NN	series
is	VBZ	be
tested	VVN	test
on	IN	on
data	NNS	datum
generated	VVN	generate
from	IN	from
a	DT	a
continuous	JJ	continuous
model	NN	model
system	NN	system
.	SENT	.
The	DT	the
study	NN	study
is	VBZ	be
done	VVN	do
in	IN	in
three	CD	three
parts	NNS	part
.	SENT	.
First	RB	first
,	,	,
the	DT	the
effects	NNS	effect
of	IN	of
sampling	VVG	sample
time	NN	time
on	IN	on
the	DT	the
number	NN	number
of	IN	of
forbidden	VVN	forbid
patterns	NNS	pattern
are	VBP	be
studied	VVN	study
on	IN	on
regularly	RB	regularly
sampled	VVN	sample
time	NN	time
series	NN	series
.	SENT	.
The	DT	the
next	JJ	next
two	CD	two
parts	NNS	part
focus	VVP	focus
on	IN	on
two	CD	two
types	NNS	type
of	IN	of
irregular-sampling	NN	irregular-sampling
,	,	,
missing	VVG	miss
data	NNS	datum
and	CC	and
timing	NN	timing
jitter	NN	jitter
.	SENT	.
It	PP	it
is	VBZ	be
shown	VVN	show
that	IN/that	that
forbidden	VVN	forbid
patterns	NNS	pattern
can	MD	can
be	VB	be
used	VVN	use
to	TO	to
detect	VV	detect
determinism	NN	determinism
in	IN	in
irregularly	RB	irregularly
sampled	VVN	sample
time	NN	time
series	NN	series
for	IN	for
low	JJ	low
degrees	NNS	degree
of	IN	of
sampling	VVG	sample
irregularity	NN	irregularity
(	(	(
as	RB	as
defined	VVN	define
in	IN	in
the	DT	the
paper	NN	paper
)	)	)
.	SENT	.
In	IN	in
addition	NN	addition
,	,	,
comments	NNS	comment
are	VBP	be
made	VVN	make
about	IN	about
the	DT	the
appropriateness	NN	appropriateness
of	IN	of
using	VVG	use
the	DT	the
BP	NP	BP
methodology	NN	methodology
to	TO	to
symbolize	VV	symbolize
irregularly	RB	irregularly
sampled	VVN	sample
time	NN	time
series	NN	series
.	SENT	.



Respiratory	JJ	respiratory
and/or	NN	and/or
lingual	NN	lingual
dysfunction	NN	dysfunction
are	VBP	be
among	IN	among
the	DT	the
first	JJ	first
motor	NN	motor
symptoms	NNS	symptom
in	IN	in
Pompe	NP	Pompe
disease	NN	disease
,	,	,
a	DT	a
disorder	NN	disorder
resulting	VVG	result
from	IN	from
absence	NN	absence
or	CC	or
dysfunction	NN	dysfunction
of	IN	of
the	DT	the
lysosomal	JJ	lysosomal
enzyme	NN	enzyme
acid	NN	acid
α-glucosidase	NN	α-glucosidase
(	(	(
GAA	NP	GAA
)	)	)
.	SENT	.
Here	RB	here
,	,	,
we	PP	we
histologically	RB	histologically
evaluated	VVD	evaluate
the	DT	the
medulla	NN	medulla
,	,	,
cervical	JJ	cervical
and	CC	and
thoracic	JJ	thoracic
spinal	JJ	spinal
cords	NNS	cord
in	IN	in
6	CD	6
weeks	NNS	week
old	JJ	old
asymptomatic	JJ	asymptomatic
Pompe	NP	Pompe
(	(	(
Gaa(-/-	NP	Gaa(-/-
)	)	)
)	)	)
mice	NNS	mouse
to	TO	to
determine	VV	determine
if	IN	if
neuropathology	NN	neuropathology
in	IN	in
respiratory	JJ	respiratory
motor	NN	motor
regions	NNS	region
has	VHZ	have
an	DT	an
early	JJ	early
onset	NN	onset
.	SENT	.
Periodic	JJ	periodic
acid-Schiff	NN	acid-Schiff
(	(	(
PAS	NP	Pas
)	)	)
staining	VVG	stain
indicated	JJ	indicated
glycogen	NN	glycogen
accumulation	NN	accumulation
was	VBD	be
exclusively	RB	exclusively
occurring	VVG	occur
in	IN	in
Gaa(-/-	NP	Gaa(-/-
)	)	)
hypoglossal	NN	hypoglossal
,	,	,
mid-cervical	NN	mid-cervical
and	CC	and
upper	JJ	upper
thoracic	JJ	thoracic
motoneurons	NNS	motoneuron
.	SENT	.
Markers	NNS	marker
of	IN	of
DNA	NN	DNA
damage	NN	damage
(	(	(
Tunel	NP	Tunel
)	)	)
and	CC	and
ongoing	JJ	ongoing
apoptosis	NN	apoptosis
(	(	(
Cleaved	NP	Cleaved
Caspase	NP	Caspase
3	CD	3
)	)	)
did	VVD	do
not	RB	not
co-localize	VV	co-localize
with	IN	with
PAS	NP	Pas
staining	VVG	stain
,	,	,
but	CC	but
were	VBD	be
prominent	JJ	prominent
in	IN	in
a	DT	a
medullary	JJ	medullary
region	NN	region
which	WDT	which
included	VVD	include
the	DT	the
nucleus	NN	nucleus
tractus	NN	tractus
solitarius	NN	solitarius
,	,	,
and	CC	and
also	RB	also
in	IN	in
the	DT	the
thoracic	JJ	thoracic
spinal	JJ	spinal
dorsal	JJ	dorsal
horn	NN	horn
.	SENT	.
We	PP	we
conclude	VVP	conclude
that	IN/that	that
respiratory-related	JJ	respiratory-related
motoneurons	NNS	motoneuron
are	VBP	be
particularly	RB	particularly
susceptible	JJ	susceptible
to	TO	to
GAA	NP	GAA
deficiency	NN	deficiency
and	CC	and
that	DT	that
neuronal	JJ	neuronal
glycogen	NN	glycogen
accumulation	NN	accumulation
and	CC	and
neurodegeneration	NN	neurodegeneration
may	MD	may
occur	VV	occur
independently	RB	independently
in	IN	in
early	JJ	early
stage	NN	stage
disease	NN	disease
.	SENT	.
The	DT	the
data	NNS	datum
support	VVP	support
early	JJ	early
therapeutic	JJ	therapeutic
intervention	NN	intervention
in	IN	in
Pompe	NP	Pompe
disease	NN	disease
.	SENT	.


Pompe	NN	Pompe
disease	NN	disease
(	(	(
PD	NP	PD
)	)	)
is	VBZ	be
a	DT	a
rare	JJ	rare
,	,	,
inherited	VVD	inherit
autosomal	JJ	autosomal
recessive	JJ	recessive
metabolic	JJ	metabolic
disorder	NN	disorder
caused	VVN	cause
by	IN	by
the	DT	the
deficiency	NN	deficiency
of	IN	of
the	DT	the
lysosomal	JJ	lysosomal
acid	NN	acid
alpha-glucosidase	NN	alpha-glucosidase
(	(	(
GAA	NP	GAA
)	)	)
enzyme	NN	enzyme
described	VVN	describe
in	IN	in
1932	CD	@card@
by	IN	by
the	DT	the
Dutch	JJ	Dutch
pathologist	NN	pathologist
Joannes	NP	Joannes
Cassianus	NP	Cassianus
Pompe	NP	Pompe
.	SENT	.
The	DT	the
prevalence	NN	prevalence
of	IN	of
PD	JJ	PD
ranges	NNS	range
from	IN	from
1:40,000	CD	@card@
to	TO	to
1:300,000	CD	@card@
births	NNS	birth
and	CC	and
depends	VVZ	depend
on	IN	on
geographic	JJ	geographic
and	CC	and
ethnic	JJ	ethnic
factors	NNS	factor
.	SENT	.
Clinical	JJ	clinical
manifestations	NNS	manifestation
may	MD	may
vary	VV	vary
from	IN	from
a	DT	a
rapidly	RB	rapidly
progressive	JJ	progressive
disabling	VVG	disable
disease	NN	disease
with	IN	with
cardiomegaly	NN	cardiomegaly
,	,	,
hepatomegaly	RB	hepatomegaly
,	,	,
weakness	NN	weakness
,	,	,
generalized	VVN	generalize
hypotonia	NN	hypotonia
,	,	,
and	CC	and
death	NN	death
within	IN	within
the	DT	the
first	JJ	first
year	NN	year
of	IN	of
life	NN	life
,	,	,
to	TO	to
a	DT	a
mild	JJ	mild
presentation	NN	presentation
characterized	VVN	characterize
by	IN	by
slowly	RB	slowly
progressive	JJ	progressive
myopathy	NN	myopathy
predominantly	RB	predominantly
involving	VVG	involve
the	DT	the
skeletal	JJ	skeletal
muscles	NNS	muscle
.	SENT	.
The	DT	the
laboratory	NN	laboratory
diagnostic	JJ	diagnostic
gold	NN	gold
standard	NN	standard
is	VBZ	be
represented	VVN	represent
by	IN	by
the	DT	the
determination	NN	determination
of	IN	of
the	DT	the
alpha-glucosidase	NN	alpha-glucosidase
activity	NN	activity
.	SENT	.
However	RB	however
,	,	,
the	DT	the
muscle	NN	muscle
histology	NN	histology
may	MD	may
also	RB	also
yield	VV	yield
the	DT	the
diagnosis	NN	diagnosis
by	IN	by
evaluating	VVG	evaluate
the	DT	the
tissular	JJ	tissular
glycogen	NN	glycogen
accumulation	NN	accumulation
.	SENT	.
Until	IN	until
recently	RB	recently
,	,	,
supportive	JJ	supportive
measures	NNS	measure
constituted	VVD	constitute
the	DT	the
unique	JJ	unique
available	JJ	available
therapy	NN	therapy
.	SENT	.
Currently	RB	currently
,	,	,
the	DT	the
administration	NN	administration
of	IN	of
the	DT	the
recombinant	JJ	recombinant
GAA	NP	GAA
is	VBZ	be
being	VBG	be
used	VVN	use
with	IN	with
promising	JJ	promising
results	NNS	result
.	SENT	.
The	DT	the
authors	NNS	author
present	VVP	present
the	DT	the
case	NN	case
of	IN	of
a	DT	a
5-month-old	JJ	5-month-old
boy	NN	boy
,	,	,
previously	RB	previously
diagnosed	VVN	diagnose
with	IN	with
hypertrophic	JJ	hypertrophic
cardiomyopathy	NN	cardiomyopathy
since	IN	since
the	DT	the
age	NN	age
of	IN	of
2	CD	2
months	NNS	month
,	,	,
who	WP	who
presented	VVD	present
acute	JJ	acute
heart	NN	heart
failure	NN	failure
accompanied	VVN	accompany
by	IN	by
biventricular	JJ	biventricular
dilation	NN	dilation
followed	VVN	follow
by	IN	by
refractory	JJ	refractory
shock	NN	shock
and	CC	and
death	NN	death
.	SENT	.
The	DT	the
autopsy	NN	autopsy
findings	NNS	finding
confirmed	VVD	confirm
the	DT	the
glycogen-accumulation	NN	glycogen-accumulation
disease	NN	disease
.	SENT	.



Pompe	NN	Pompe
disease	NN	disease
is	VBZ	be
an	DT	an
inherited	VVN	inherit
disorder	NN	disorder
notable	JJ	notable
for	IN	for
severe	JJ	severe
,	,	,
progressive	JJ	progressive
ventilatory	JJ	ventilatory
compromise	NN	compromise
.	SENT	.
Although	IN	although
ventilatory	JJ	ventilatory
failure	NN	failure
has	VHZ	have
been	VBN	be
attributed	VVN	attribute
to	TO	to
myofiber	NN	myofiber
dysfunction	NN	dysfunction
secondary	JJ	secondary
to	TO	to
diaphragmatic	JJ	diaphragmatic
glycogen	NN	glycogen
accumulation	NN	accumulation
,	,	,
neural	JJ	neural
involvement	NN	involvement
of	IN	of
the	DT	the
phrenic	JJ	phrenic
motor	NN	motor
system	NN	system
is	VBZ	be
also	RB	also
a	DT	a
prominent	JJ	prominent
feature	NN	feature
.	SENT	.
Direct	JJ	direct
diaphragm	NN	diaphragm
pacing	VVG	pace
supplements	NNS	supplement
respiratory	JJ	respiratory
function	NN	function
in	IN	in
other	JJ	other
disorders	NNS	disorder
of	IN	of
the	DT	the
phrenic	JJ	phrenic
motor	NN	motor
system	NN	system
.	SENT	.
Accordingly	RB	accordingly
,	,	,
it	PP	it
is	VBZ	be
hypothesized	VVN	hypothesize
that	IN/that	that
augmented	JJ	augmented
neuromuscular	JJ	neuromuscular
activity	NN	activity
via	IN	via
diaphragm	NN	diaphragm
pacing	VVG	pace
would	MD	would
promote	VV	promote
weaning	VVG	wean
from	IN	from
mechanical	JJ	mechanical
ventilation	NN	ventilation
in	IN	in
patients	NNS	patient
with	IN	with
Pompe	NP	Pompe
disease	NN	disease
who	WP	who
are	VBP	be
unresponsive	JJ	unresponsive
to	TO	to
conventional	JJ	conventional
,	,	,
muscle-directed	JJ	muscle-directed
treatments.Three	NN	treatments.Three
patients	NNS	patient
with	IN	with
Pompe	NP	Pompe
disease	NN	disease
developed	VVD	develop
diaphragm	NN	diaphragm
paresis	NN	paresis
that	WDT	that
resulted	VVD	result
in	IN	in
chronic	JJ	chronic
mechanical	JJ	mechanical
ventilation	NN	ventilation
dependence	NN	dependence
.	SENT	.
After	IN	after
preoperative	JJ	preoperative
inspiratory	JJ	inspiratory
muscle	NN	muscle
strengthening	NN	strengthening
exercises	NNS	exercise
failed	VVD	fail
to	TO	to
improve	VV	improve
function	NN	function
,	,	,
fine-wire	NN	fine-wire
pacing	VVG	pace
electrodes	NNS	electrode
were	VBD	be
laparoscopically	RB	laparoscopically
implanted	VVN	implant
into	IN	into
the	DT	the
diaphragm	NN	diaphragm
.	SENT	.
Diaphragm	NN	diaphragm
conditioning	NN	conditioning
was	VBD	be
initiated	VVN	initiate
the	DT	the
first	JJ	first
postoperative	JJ	postoperative
week	NN	week
and	CC	and
consisted	VVD	consist
of	IN	of
gradual	JJ	gradual
increases	NNS	increase
in	IN	in
stimulation	NN	stimulation
parameters	NNS	parameter
,	,	,
lengthening	VVG	lengthen
of	IN	of
stimulation	NN	stimulation
sessions	NNS	session
,	,	,
and	CC	and
ventilator	NN	ventilator
weaning	VVG	wean
.	SENT	.
Ventilation	NN	ventilation
and	CC	and
intramuscular	JJ	intramuscular
electromyographic	JJ	electromyographic
activity	NN	activity
were	VBD	be
recorded	VVN	record
periodically	RB	periodically
during	IN	during
conditioning	NN	conditioning
to	TO	to
quantify	VV	quantify
diaphragm	NN	diaphragm
neuromuscular	JJ	neuromuscular
function.During	NN	function.During
paced	VVN	pace
breathing	NN	breathing
without	IN	without
mechanical	JJ	mechanical
ventilation	NN	ventilation
,	,	,
tidal	JJ	tidal
volumes	NNS	volume
increased	VVD	increase
,	,	,
and	CC	and
2	CD	2
patients	NNS	patient
were	VBD	be
weaned	VVN	wean
from	IN	from
daytime	JJ	daytime
ventilator	NN	ventilator
dependence	NN	dependence
within	IN	within
the	DT	the
first	JJ	first
3	CD	3
months	NNS	month
of	IN	of
pacing	VVG	pace
,	,	,
which	WDT	which
has	VHZ	have
been	VBN	be
sustained	VVN	sustain
over	IN	over
the	DT	the
long-term	JJ	long-term
.	SENT	.
A	DT	a
third	JJ	third
patient	NN	patient
reduced	VVD	reduce
reliance	NN	reliance
on	IN	on
daytime	JJ	daytime
ventilation	NN	ventilation
,	,	,
but	CC	but
weaning	VVG	wean
was	VBD	be
delayed	VVN	delay
by	IN	by
malacia	NNS	malacia
of	IN	of
the	DT	the
large	JJ	large
airways	NNS	airway
.	SENT	.
In	IN	in
all	DT	all
patients	NNS	patient
,	,	,
pacing	VVG	pace
appeared	VVD	appear
to	TO	to
facilitate	VV	facilitate
spontaneous	JJ	spontaneous
phrenic	JJ	phrenic
motor	NN	motor
unit	NN	unit
activity	NN	activity
during	IN	during
independent	JJ	independent
breathing	NN	breathing
without	IN	without
ventilator	NN	ventilator
or	CC	or
pacer	NN	pacer
support.The	NN	support.The
findings	NNS	finding
are	VBP	be
consistent	JJ	consistent
with	IN	with
the	DT	the
view	NN	view
that	IN/that	that
diaphragm	NN	diaphragm
pacing	VVG	pace
has	VHZ	have
potential	JJ	potential
rehabilitative	JJ	rehabilitative
value	NN	value
to	TO	to
reduce	VV	reduce
reliance	NN	reliance
on	IN	on
mechanical	JJ	mechanical
ventilation	NN	ventilation
in	IN	in
people	NNS	people
with	IN	with
Pompe	NP	Pompe
disease	NN	disease
,	,	,
but	CC	but
further	JJR	further
study	NN	study
is	VBZ	be
needed	VVN	need
.	SENT	.
Diaphragm	NN	diaphragm
pacing	VVG	pace
represents	VVZ	represent
a	DT	a
paradigm	NN	paradigm
shift	NN	shift
in	IN	in
the	DT	the
management	NN	management
of	IN	of
respiratory	JJ	respiratory
insufficiency	NN	insufficiency
for	IN	for
Pompe	NP	Pompe
disease	NN	disease
that	WDT	that
warrants	VVZ	warrant
further	RBR	further
controlled	VVN	control
examination	NN	examination
.	SENT	.



Pompe	NN	Pompe
disease	NN	disease
,	,	,
also	RB	also
known	VVN	know
as	IN	as
glycogen	NN	glycogen
storage	NN	storage
disease	NN	disease
type	NN	type
II	NP	II
,	,	,
is	VBZ	be
caused	VVN	cause
by	IN	by
acid	JJ	acid
maltase	NN	maltase
deficiency	NN	deficiency
,	,	,
and	CC	and
can	MD	can
lead	VV	lead
to	TO	to
lysosomal	JJ	lysosomal
glycogen	NN	glycogen
storage	NN	storage
.	SENT	.
The	DT	the
primal	JJ	primal
manifestations	NNS	manifestation
may	MD	may
be	VB	be
observed	VVN	observe
in	IN	in
children	NNS	child
and	CC	and
adults	NNS	adult
,	,	,
and	CC	and
also	RB	also
in	IN	in
infants	NNS	infant
.	SENT	.
In	IN	in
general	NN	general
,	,	,
the	DT	the
clinical	JJ	clinical
spectrum	NN	spectrum
in	IN	in
infants	NNS	infant
is	VBZ	be
more	RBR	more
progressive	JJ	progressive
and	CC	and
lethal	JJ	lethal
than	IN	than
that	IN/that	that
in	IN	in
older	JJR	old
patients	NNS	patient
.	SENT	.
This	DT	this
case	NN	case
report	NN	report
describes	VVZ	describe
the	DT	the
case	NN	case
of	IN	of
a	DT	a
newborn	JJ	newborn
who	WP	who
was	VBD	be
found	VVN	find
to	TO	to
have	VH	have
cardiac	JJ	cardiac
hypertrophy	NN	hypertrophy
,	,	,
hepatomegaly	JJ	hepatomegaly
and	CC	and
elevated	JJ	elevated
serum	NN	serum
enzyme	NN	enzyme
levels	NNS	level
,	,	,
which	WDT	which
was	VBD	be
characterized	VVN	characterize
by	IN	by
an	DT	an
aspartate	JJ	aspartate
aminotransferase	NN	aminotransferase
level	NN	level
of	IN	of
95	CD	@card@
U/l	NP	U/l
,	,	,
lactate	NN	lactate
dehydrogenase	NN	dehydrogenase
level	NN	level
of	IN	of
778	CD	@card@
U/l	NN	U/l
and	CC	and
creatine	NN	creatine
kinase	NN	kinase
level	NN	level
of	IN	of
1,299	CD	@card@
U/l	NN	U/l
.	SENT	.
On	IN	on
the	DT	the
basis	NN	basis
of	IN	of
the	DT	the
clinical	JJ	clinical
signs	NNS	sign
and	CC	and
laboratory	NN	laboratory
results	NNS	result
,	,	,
dried	VVD	dry
blood	NN	blood
spots	NNS	spot
from	IN	from
the	DT	the
baby	NN	baby
were	VBD	be
tested	VVN	test
to	TO	to
determine	VV	determine
the	DT	the
acid	JJ	acid
α-glucosidase	NN	α-glucosidase
(	(	(
GAA	NP	GAA
)	)	)
activity	NN	activity
,	,	,
and	CC	and
the	DT	the
result	NN	result
confirmed	VVD	confirm
that	IN/that	that
the	DT	the
GAA	NP	GAA
activity	NN	activity
was	VBD	be
only	RB	only
0.10	CD	@card@
pmol/punch/h	NN	pmol/punch/h
(	(	(
normal	JJ	normal
reference	NN	reference
range	NN	range
,	,	,
2.88-89.02	CD	@card@
pmol/punch/h	NN	pmol/punch/h
)	)	)
at	IN	at
pH	NN	pH
3.8	CD	@card@
,	,	,
which	WDT	which
was	VBD	be
clearly	RB	clearly
lower	JJR	low
than	IN	than
the	DT	the
normal	JJ	normal
range	NN	range
,	,	,
leading	VVG	lead
to	TO	to
a	DT	a
diagnosis	NN	diagnosis
of	IN	of
Pompe	NP	Pompe
disease	NN	disease
.	SENT	.
Pompe	NN	Pompe
disease	NN	disease
is	VBZ	be
incurable	JJ	incurable
,	,	,
and	CC	and
before	IN	before
the	DT	the
introduction	NN	introduction
of	IN	of
enzyme	NN	enzyme
replacement	NN	replacement
therapy	NN	therapy
(	(	(
ERT	NN	ERT
)	)	)
,	,	,
pain	NN	pain
relief	NN	relief
was	VBD	be
the	DT	the
main	JJ	main
treatment	NN	treatment
.	SENT	.
Recognizing	VVG	recognize
this	DT	this
disease	NN	disease
earlier	RBR	earlier
and	CC	and
starting	VVG	start
ERT	NN	ERT
in	IN	in
infants	NNS	infant
prior	RB	prior
to	TO	to
the	DT	the
development	NN	development
of	IN	of
clinical	JJ	clinical
symptoms	NNS	symptom
is	VBZ	be
likely	JJ	likely
to	TO	to
improve	VV	improve
the	DT	the
quality	NN	quality
of	IN	of
life	NN	life
of	IN	of
patients	NNS	patient
.	SENT	.


In	IN	in
the	DT	the
light	NN	light
of	IN	of
clinical	JJ	clinical
experience	NN	experience
in	IN	in
infantile	JJ	infantile
onset	NN	onset
Pompe	NN	Pompe
patients	NNS	patient
,	,	,
the	DT	the
immunological	JJ	immunological
impact	NN	impact
on	IN	on
the	DT	the
tolerability	NN	tolerability
and	CC	and
long-term	JJ	long-term
efficacy	NN	efficacy
of	IN	of
enzyme	NN	enzyme
replacement	NN	replacement
therapy	NN	therapy
(	(	(
ERT	NN	ERT
)	)	)
for	IN	for
lysosomal	JJ	lysosomal
storage	NN	storage
disorders	NNS	disorder
has	VHZ	have
come	VVN	come
under	IN	under
renewed	JJ	renewed
scrutiny	NN	scrutiny
.	SENT	.
This	DT	this
article	NN	article
details	NNS	detail
the	DT	the
currently	RB	currently
proposed	VVN	propose
immunological	JJ	immunological
mechanisms	NNS	mechanism
involved	VVN	involve
in	IN	in
the	DT	the
development	NN	development
of	IN	of
anti-drug	JJ	anti-drug
antibodies	NNS	antibody
and	CC	and
the	DT	the
current	JJ	current
therapies	NNS	therapy
used	VVN	use
in	IN	in
their	PP$	their
treatment	NN	treatment
.	SENT	.
Given	VVN	give
the	DT	the
current	JJ	current
understanding	NN	understanding
of	IN	of
the	DT	the
adaptive	JJ	adaptive
immune	JJ	immune
response	NN	response
,	,	,
it	PP	it
focuses	VVZ	focus
particularly	RB	particularly
on	IN	on
T	NN	T
cell	NN	cell
dependent	JJ	dependent
mechanisms	NNS	mechanism
and	CC	and
the	DT	the
paradigm	NN	paradigm
of	IN	of
using	VVG	use
lymphocytic	JJ	lymphocytic
negative	JJ	negative
selection	NN	selection
as	IN	as
a	DT	a
predictor	NN	predictor
of	IN	of
antibody	NN	antibody
formation	NN	formation
.	SENT	.
This	DT	this
concept	NN	concept
originally	RB	originally
postulated	VVN	postulate
in	IN	in
the	DT	the
1970s	NNS	1970s
,	,	,
stipulated	VVD	stipulate
that	IN/that	that
the	DT	the
genotypically	RB	genotypically
determined	VVN	determine
lack	NN	lack
of	IN	of
production	NN	production
or	CC	or
production	NN	production
of	IN	of
a	DT	a
variant	JJ	variant
protein	NN	protein
determines	VVZ	determine
an	DT	an
individual	NN	individual
lymphocytic	JJ	lymphocytic
repertoire	NN	repertoire
.	SENT	.
This	DT	this
in	IN	in
turn	NN	turn
is	VBZ	be
the	DT	the
key	JJ	key
factor	NN	factor
in	IN	in
determining	VVG	determine
the	DT	the
potential	JJ	potential
severity	NN	severity
of	IN	of
an	DT	an
individual	NN	individual
immunological	JJ	immunological
response	NN	response
to	TO	to
ERT	NN	ERT
.	SENT	.
It	PP	it
also	RB	also
highlights	VVZ	highlight
the	DT	the
need	NN	need
for	IN	for
immunological	JJ	immunological
assay	NN	assay
standardization	NN	standardization
particularly	RB	particularly
those	DT	those
looking	VVG	look
at	IN	at
describing	VVG	describe
the	DT	the
degree	NN	degree
of	IN	of
functional	JJ	functional
impact	NN	impact
,	,	,
robust	JJ	robust
biochemical	JJ	biochemical
or	CC	or
clinical	JJ	clinical
endpoints	NNS	endpoints
and	CC	and
detailed	JJ	detailed
patient	JJ	patient
subgroup	NN	subgroup
identification	NN	identification
if	IN	if
the	DT	the
true	JJ	true
evaluations	NNS	evaluation
of	IN	of
impact	NN	impact
are	VBP	be
to	TO	to
be	VB	be
realised	VVN	realise
.	SENT	.



Pompe	NN	Pompe
disease	NN	disease
is	VBZ	be
an	DT	an
autosomal	JJ	autosomal
recessive	JJ	recessive
disease	NN	disease
resulting	VVG	result
from	IN	from
deficiency	NN	deficiency
of	IN	of
the	DT	the
acid	JJ	acid
alpha-glucosidase	NN	alpha-glucosidase
(	(	(
GAA	NP	GAA
)	)	)
.	SENT	.
The	DT	the
late-onset	NN	late-onset
Pompe	NP	Pompe
Disease	NP	Disease
(	(	(
LOPD	NP	LOPD
)	)	)
patients	NNS	patient
develop	VVP	develop
muscular	JJ	muscular
and	CC	and
respiratory	JJ	respiratory
complications	NNS	complication
later	RBR	later
in	IN	in
life	NN	life
.	SENT	.
We	PP	we
describe	VVP	describe
a	DT	a
retrospective	JJ	retrospective
observational	JJ	observational
cohort	NN	cohort
study	NN	study
including	VVG	include
22	CD	@card@
patients	NNS	patient
with	IN	with
LOPD	NP	LOPD
.	SENT	.
The	DT	the
cohort	NN	cohort
was	VBD	be
assessed	VVN	assess
at	IN	at
baseline	NN	baseline
before	IN	before
Enzyme	NP	Enzyme
Replacement	NP	Replacement
Therapy	NP	Therapy
(	(	(
ERT	NN	ERT
)	)	)
with	IN	with
alglucosidase	NN	alglucosidase
alpha	NN	alpha
(	(	(
20mg/kg	JJ	20mg/kg
biweekly	NN	biweekly
)	)	)
was	VBD	be
commenced	VVD	commence
and	CC	and
subsequently	RB	subsequently
relevant	JJ	relevant
information	NN	information
was	VBD	be
collected	VVN	collect
at	IN	at
2	CD	2
,	,	,
4	CD	4
and	CC	and
5years	NNS	5years
later	RBR	later
.	SENT	.
The	DT	the
median	JJ	median
age	NN	age
of	IN	of
the	DT	the
patients	NNS	patient
at	IN	at
study	NN	study
entry	NN	entry
was	VBD	be
44years	JJ	44years
(	(	(
16-64years	JJ	16-64years
)	)	)
,	,	,
with	IN	with
median	JJ	median
disease	NN	disease
duration	NN	duration
of	IN	of
11.5years	JJ	11.5years
(	(	(
4-31years	JJ	4-31years
)	)	)
.	SENT	.
At	IN	at
baseline	NN	baseline
,	,	,
10	CD	@card@
patients	NNS	patient
(	(	(
45	CD	@card@
%	NN	%
)	)	)
could	MD	could
walk	VV	walk
without	IN	without
support	NN	support
,	,	,
12	CD	@card@
(	(	(
55	CD	@card@
%	NN	%
)	)	)
could	MD	could
walk	VV	walk
with	IN	with
unilateral	JJ	unilateral
or	CC	or
bilateral	JJ	bilateral
support	NN	support
including	VVG	include
3/12	CD	@card@
were	VBD	be
wheelchair	NN	wheelchair
bound	VVN	bind
.	SENT	.
Mean	NN	mean
predicted	VVD	predict
FVC	NP	FVC
%	NN	%
was	VBD	be
55.7	CD	@card@
(	(	(
95	CD	@card@
%	NN	%
CI	NP	CI
45-66	CD	@card@
)	)	)
of	IN	of
predicted	VVN	predict
normal	JJ	normal
at	IN	at
baseline	NN	baseline
and	CC	and
showed	VVD	show
no	DT	no
significant	JJ	significant
change	NN	change
after	IN	after
5years	NNS	5years
(	(	(
54.6	CD	@card@
(	(	(
95	CD	@card@
%	NN	%
CI	NP	CI
43-66	CD	@card@
)	)	)
)	)	)
,	,	,
(	(	(
all	DT	all
p=0.9815	NN	p=0.9815
)	)	)
.	SENT	.
Mean	JJ	mean
FVC	NP	FVC
%	NN	%
supine	NN	supine
was	VBD	be
41.8	CD	@card@
(	(	(
95	CD	@card@
%	NN	%
CI	NP	CI
33.8-49	CD	@card@
)	)	)
of	IN	of
predicted	VVN	predict
normal	JJ	normal
at	IN	at
baseline	NN	baseline
and	CC	and
remained	VVD	remain
significantly	RB	significantly
unchanged	JJ	unchanged
at	IN	at
5years	NNS	5years
(	(	(
48.4	CD	@card@
(	(	(
95	CD	@card@
%	NN	%
CI	NP	CI
37-59.6	CD	@card@
)	)	)
)	)	)
,	,	,
(	(	(
all	DT	all
p=0.8680	NN	p=0.8680
)	)	)
.	SENT	.
The	DT	the
overnight	JJ	overnight
non-invasive	JJ	non-invasive
ventilator	NN	ventilator
dependence	NN	dependence
increased	VVN	increase
by	IN	by
18.2	CD	@card@
%	NN	%
as	IN	as
compared	VVN	compare
with	IN	with
baseline	NN	baseline
and	CC	and
requirement	NN	requirement
of	IN	of
mobility	NN	mobility
aids	NNS	aid
increased	VVN	increase
during	IN	during
this	DT	this
period	NN	period
by	IN	by
5.2	CD	@card@
%	NN	%
as	IN	as
compared	VVN	compare
with	IN	with
the	DT	the
baseline	NN	baseline
.	SENT	.
Mean	VV	mean
walking	VVG	walk
distance	NN	distance
at	IN	at
6min	JJ	6min
walk	NN	walk
test	NN	test
was	VBD	be
411.5	CD	@card@
(	(	(
95	CD	@card@
%	NN	%
CI	NP	CI
338-485	CD	@card@
)	)	)
at	IN	at
baseline	NN	baseline
,	,	,
266.5	CD	@card@
(	(	(
95	CD	@card@
%	NN	%
CI	NP	CI
187-346	CD	@card@
)	)	)
m	NN	m
at	IN	at
2years	NNS	2years
,	,	,
238.6	CD	@card@
(	(	(
95	CD	@card@
%	NN	%
CI	NP	CI
162-315	CD	@card@
)	)	)
m	NN	m
at	IN	at
4years	NNS	4years
and	CC	and
286.8	CD	@card@
(	(	(
95	CD	@card@
%	NN	%
CI	NP	CI
203-370	CD	@card@
)	)	)
m	NN	m
at	IN	at
5years	JJ	5years
(	(	(
p=0.1981	JJ	p=0.1981
;	:	;
ANOVA	NP	ANOVA
was	VBD	be
completed	VVN	complete
only	RB	only
for	IN	for
14	CD	@card@
patients	NNS	patient
)	)	)
.	SENT	.
A	DT	a
gradual	JJ	gradual
decline	NN	decline
in	IN	in
FVC	NP	FVC
%	NN	%
predicted	VVD	predict
was	VBD	be
noted	VVN	note
only	RB	only
in	IN	in
four	CD	four
cases	NNS	case
and	CC	and
a	DT	a
decline	NN	decline
in	IN	in
FVC	NP	FVC
%	NN	%
supine	NN	supine
in	IN	in
two	CD	two
other	JJ	other
.	SENT	.
Only	RB	only
one	CD	one
patient	NN	patient
showed	VVD	show
a	DT	a
decline	NN	decline
in	IN	in
both	DT	both
pulmonary	JJ	pulmonary
function	NN	function
tests	NNS	test
.	SENT	.
In	IN	in
all	DT	all
remaining	VVG	remain
cases	NNS	case
(	(	(
17/22	CD	@card@
)	)	)
respiratory	JJ	respiratory
function	NN	function
remains	VVZ	remain
stable	JJ	stable
.	SENT	.
In	IN	in
conclusion	NN	conclusion
overall	JJ	overall
pulmonary	JJ	pulmonary
function	NN	function
tests	NNS	test
and	CC	and
mobility	NN	mobility
remained	VVD	remain
stable	JJ	stable
for	IN	for
5years	NNS	5years
in	IN	in
majority	NN	majority
of	IN	of
patients	NNS	patient
on	IN	on
ERT	NN	ERT
.	SENT	.
However	RB	however
,	,	,
in	IN	in
some	DT	some
patients	NNS	patient
they	PP	they
continued	VVD	continue
to	TO	to
decline	VV	decline
in	IN	in
spite	NN	spite
of	IN	of
ERT	NN	ERT
resulting	VVG	result
in	IN	in
increased	VVN	increase
number	NN	number
of	IN	of
patients	NNS	patient
requiring	VVG	require
ventilation	NN	ventilation
and	CC	and
increase	NN	increase
wheel	NN	wheel
chair	NN	chair
dependence	NN	dependence
at	IN	at
the	DT	the
end	NN	end
of	IN	of
5years	NNS	5years
.	SENT	.



Pompe	NP	Pompe
or	CC	or
Glycogen	NP	Glycogen
Storage	NP	Storage
Disease	NP	Disease
type	NN	type
II	NP	II
(	(	(
GSD-II	NP	GSD-II
)	)	)
is	VBZ	be
a	DT	a
genetic	JJ	genetic
disorder	NN	disorder
affecting	VVG	affect
both	DT	both
cardiac	JJ	cardiac
and	CC	and
skeletal	JJ	skeletal
muscle	NN	muscle
.	SENT	.
Historically	RB	historically
,	,	,
patients	NNS	patient
with	IN	with
the	DT	the
infantile	JJ	infantile
form	NN	form
usually	RB	usually
die	VV	die
within	IN	within
the	DT	the
first	JJ	first
year	NN	year
of	IN	of
life	NN	life
due	JJ	due
to	TO	to
cardiac	JJ	cardiac
and	CC	and
respiratory	JJ	respiratory
failure	NN	failure
.	SENT	.
Recently	RB	recently
a	DT	a
promising	JJ	promising
enzyme	NN	enzyme
replacement	NN	replacement
therapy	NN	therapy
has	VHZ	have
resulted	VVN	result
in	IN	in
improved	VVN	improve
clinical	JJ	clinical
outcomes	NNS	outcome
and	CC	and
a	DT	a
resurgence	NN	resurgence
of	IN	of
elective	JJ	elective
anesthesia	NN	anesthesia
for	IN	for
these	DT	these
patients	NNS	patient
.	SENT	.
Understanding	VVG	understand
the	DT	the
unique	JJ	unique
cardiac	JJ	cardiac
physiology	NN	physiology
in	IN	in
patients	NNS	patient
with	IN	with
GSD-II	NP	GSD-II
is	VBZ	be
essential	JJ	essential
to	TO	to
providing	VVG	provide
safe	JJ	safe
general	JJ	general
anesthesia	NN	anesthesia
.	SENT	.
Additional	JJ	additional
care	NN	care
in	IN	in
maximizing	VVG	maximize
coronary	JJ	coronary
perfusion	NN	perfusion
pressure	NN	pressure
and	CC	and
minimizing	VVG	minimize
arrhythmia	NN	arrhythmia
risk	NN	risk
must	MD	must
be	VB	be
given	VVN	give
.	SENT	.
For	IN	for
these	DT	these
reasons	NNS	reason
,	,	,
it	PP	it
is	VBZ	be
recommended	VVN	recommend
that	IN/that	that
anesthesia	NN	anesthesia
for	IN	for
infantile	JJ	infantile
Pompe	NP	Pompe
patients	NNS	patient
should	MD	should
specifically	RB	specifically
avoid	VV	avoid
propofol	NN	propofol
or	CC	or
high	JJ	high
concentrations	NNS	concentration
of	IN	of
sevoflurane	NN	sevoflurane
and	CC	and
,	,	,
instead	RB	instead
,	,	,
use	VVP	use
an	DT	an
agent	NN	agent
such	JJ	such
as	IN	as
ketamine	NN	ketamine
as	IN	as
the	DT	the
cornerstone	NN	cornerstone
for	IN	for
induction	NN	induction
in	IN	in
order	NN	order
to	TO	to
better	RBR	well
support	VV	support
coronary	JJ	coronary
perfusion	NN	perfusion
pressure	NN	pressure
and	CC	and
to	TO	to
avoid	VV	avoid
decreasing	VVG	decrease
diastolic	JJ	diastolic
blood	NN	blood
pressure	NN	pressure
(	(	(
DBP	NP	DBP
)	)	)
with	IN	with
vasodilatory	JJ	vasodilatory
agents	NNS	agent
.	SENT	.
We	PP	we
present	VVP	present
the	DT	the
anesthetic	JJ	anesthetic
technique	NN	technique
in	IN	in
a	DT	a
case	NN	case
of	IN	of
infantile	JJ	infantile
type	NN	type
Pompe	NN	Pompe
disease	NN	disease
.	SENT	.



Enzyme	NN	enzyme
and	CC	and
gene	NN	gene
replacement	NN	replacement
strategies	NNS	strategy
have	VHP	have
developed	VVN	develop
into	IN	into
viable	JJ	viable
therapeutic	JJ	therapeutic
approaches	NNS	approach
for	IN	for
the	DT	the
treatment	NN	treatment
of	IN	of
Pompe	NP	Pompe
disease	NN	disease
(	(	(
acid	JJ	acid
α-glucosidase	NN	α-glucosidase
(	(	(
GAA	NP	GAA
)	)	)
deficiency	NN	deficiency
)	)	)
.	SENT	.
Unfortunately	RB	unfortunately
,	,	,
the	DT	the
introduction	NN	introduction
of	IN	of
GAA	NP	GAA
and	CC	and
viral	JJ	viral
vectors	NNS	vector
encoding	VVG	encode
the	DT	the
enzyme	NN	enzyme
can	MD	can
lead	VV	lead
to	TO	to
detrimental	JJ	detrimental
immune	JJ	immune
responses	NNS	response
that	WDT	that
attenuate	VVP	attenuate
treatment	NN	treatment
benefits	NNS	benefit
and	CC	and
can	MD	can
impact	VV	impact
patient	JJ	patient
safety	NN	safety
.	SENT	.
Preclinical	JJ	preclinical
and	CC	and
clinical	JJ	clinical
experience	NN	experience
in	IN	in
addressing	VVG	address
humoral	JJ	humoral
responses	NNS	response
toward	IN	toward
enzyme	NN	enzyme
and	CC	and
gene	NN	gene
therapy	NN	therapy
for	IN	for
Pompe	NP	Pompe
disease	NN	disease
have	VHP	have
provided	VVN	provide
greater	JJR	great
understanding	NN	understanding
of	IN	of
the	DT	the
immunological	JJ	immunological
consequences	NNS	consequence
of	IN	of
the	DT	the
provided	VVN	provide
therapy	NN	therapy
.	SENT	.
B-	NP	B-
and	CC	and
T-cell	NN	T-cell
modulation	NN	modulation
has	VHZ	have
been	VBN	be
shown	VVN	show
to	TO	to
be	VB	be
effective	JJ	effective
in	IN	in
preventing	VVG	prevent
infusion-associated	JJ	infusion-associated
reactions	NNS	reaction
during	IN	during
enzyme	NN	enzyme
replacement	NN	replacement
therapy	NN	therapy
in	IN	in
patients	NNS	patient
and	CC	and
has	VHZ	have
shown	VVN	show
similar	JJ	similar
success	NN	success
in	IN	in
the	DT	the
context	NN	context
of	IN	of
gene	NN	gene
therapy	NN	therapy
.	SENT	.
Additional	JJ	additional
techniques	NNS	technique
to	TO	to
induce	VV	induce
humoral	JJ	humoral
tolerance	NN	tolerance
for	IN	for
Pompe	NP	Pompe
disease	NN	disease
have	VHP	have
been	VBN	be
the	DT	the
targeted	JJ	targeted
expression	NN	expression
or	CC	or
delivery	NN	delivery
of	IN	of
GAA	NP	GAA
to	TO	to
discrete	JJ	discrete
cell	NN	cell
types	NNS	type
or	CC	or
tissues	NNS	tissue
such	JJ	such
as	IN	as
the	DT	the
gut-associated	JJ	gut-associated
lymphoid	JJ	lymphoid
tissues	NNS	tissue
,	,	,
red	JJ	red
blood	NN	blood
cells	NNS	cell
,	,	,
hematopoietic	JJ	hematopoietic
stem	NN	stem
cells	NNS	cell
,	,	,
and	CC	and
the	DT	the
liver	NN	liver
.	SENT	.
Research	NN	research
into	IN	into
overcoming	VVG	overcome
preexisting	VVG	preexist
immunity	NN	immunity
through	IN	through
immunomodulation	NN	immunomodulation
and	CC	and
gene	NN	gene
transfer	NN	transfer
are	VBP	be
becoming	VVG	become
increasingly	RB	increasingly
important	JJ	important
to	TO	to
achieve	VV	achieve
long-term	JJ	long-term
efficacy	NN	efficacy
.	SENT	.
This	DT	this
review	NN	review
highlights	VVZ	highlight
the	DT	the
advances	NNS	advance
in	IN	in
therapies	NNS	therapy
as	RB	as
well	RB	well
as	IN	as
the	DT	the
improved	VVN	improve
understanding	NN	understanding
of	IN	of
the	DT	the
molecular	JJ	molecular
mechanisms	NNS	mechanism
involved	VVN	involve
in	IN	in
the	DT	the
humoral	JJ	humoral
immune	JJ	immune
response	NN	response
with	IN	with
emphasis	NN	emphasis
on	IN	on
methods	NNS	method
employed	VVN	employ
to	TO	to
overcome	VV	overcome
responses	NNS	response
associated	VVN	associate
with	IN	with
enzyme	NN	enzyme
and	CC	and
gene	NN	gene
therapies	NNS	therapy
for	IN	for
Pompe	NP	Pompe
disease	NN	disease
.	SENT	.



In	IN	in
almost	RB	almost
a	DT	a
third	JJ	third
of	IN	of
stroke	NN	stroke
in	IN	in
young	JJ	young
cases	NNS	case
,	,	,
etiology	NN	etiology
remains	VVZ	remain
unclear	JJ	unclear
.	SENT	.
We	PP	we
report	VVP	report
a	DT	a
radiological	JJ	radiological
entity	NN	entity
which	WDT	which
might	MD	might
give	VV	give
a	DT	a
clue	NN	clue
toward	IN	toward
detection	NN	detection
of	IN	of
late	JJ	late
onset	NN	onset
Pompe	NP	Pompe
disease	NN	disease
in	IN	in
some	DT	some
cases.Here	NN	cases.Here
we	PP	we
report	VVP	report
two	CD	two
cases	NNS	case
of	IN	of
stroke	NN	stroke
in	IN	in
young	JJ	young
in	IN	in
which	WDT	which
evaluation	NN	evaluation
led	VVD	lead
to	TO	to
diagnosis	NN	diagnosis
of	IN	of
late	JJ	late
onset	NN	onset
Pompe	NP	Pompe
disease	NN	disease
.	SENT	.
Both	DT	both
patients	NNS	patient
presented	VVN	present
with	IN	with
recurrent	JJ	recurrent
stroke	NN	stroke
.	SENT	.
On	IN	on
evaluation	NN	evaluation
,	,	,
one	CD	one
of	IN	of
them	PP	them
was	VBD	be
found	VVN	find
to	TO	to
have	VH	have
slowly	RB	slowly
progressive	JJ	progressive
predominantly	RB	predominantly
proximal	JJ	proximal
quadriparesis	NN	quadriparesis
.	SENT	.
His	PP$	his
muscle	NN	muscle
biopsy	NN	biopsy
showed	VVD	show
Pompe	NP	Pompe
disease	NN	disease
and	CC	and
had	VHD	have
dolichoectasia	NN	dolichoectasia
of	IN	of
posterior	JJ	posterior
circulation	NN	circulation
vessels	NNS	vessel
.	SENT	.
The	DT	the
other	JJ	other
patient	NN	patient
did	VVD	do
not	RB	not
have	VH	have
any	DT	any
muscle	NN	muscle
weakness	NN	weakness
.	SENT	.
Detailed	JJ	detailed
workup	NN	workup
for	IN	for
stroke	NN	stroke
in	IN	in
young	JJ	young
was	VBD	be
negative	JJ	negative
,	,	,
but	CC	but
as	IN	as
angiogram	NN	angiogram
showed	VVD	show
intracranial	JJ	intracranial
vessel	NN	vessel
dolichoectasia	NN	dolichoectasia
,	,	,
he	PP	he
was	VBD	be
also	RB	also
investigated	VVN	investigate
and	CC	and
found	VVN	find
to	TO	to
have	VH	have
Pompe	NP	Pompe
disease.We	NNS	disease.We
conclude	VVP	conclude
that	IN/that	that
dolichoectasia	NNS	dolichoectasia
of	IN	of
intracranial	JJ	intracranial
vessels	NNS	vessel
in	IN	in
cases	NNS	case
with	IN	with
stroke	NN	stroke
in	IN	in
young	JJ	young
,	,	,
with	IN	with
or	CC	or
without	IN	without
muscle	NN	muscle
weakness	NN	weakness
,	,	,
should	MD	should
raise	VV	raise
a	DT	a
differential	NN	differential
of	IN	of
late	JJ	late
onset	NN	onset
Pompe	NP	Pompe
disease	NN	disease
.	SENT	.
This	DT	this
being	VBG	be
one	CD	one
of	IN	of
the	DT	the
few	JJ	few
treatable	JJ	treatable
disorders	NNS	disorder
makes	VVZ	make
the	DT	the
diagnosis	NN	diagnosis
all	RB	all
the	DT	the
more	RBR	more
important	JJ	important


Infantile	JJ	infantile
Onset	NN	onset
Pompe	NP	Pompe
Disease	NP	Disease
(	(	(
IOPD	NP	IOPD
)	)	)
is	VBZ	be
a	DT	a
rare	JJ	rare
autosomal	JJ	autosomal
recessive	JJ	recessive
neuromuscular	JJ	neuromuscular
disorder	NN	disorder
.	SENT	.
It	PP	it
is	VBZ	be
associated	VVN	associate
with	IN	with
cardiomegaly	NN	cardiomegaly
,	,	,
hypotonia	NN	hypotonia
,	,	,
paresis	NN	paresis
,	,	,
and	CC	and
death	NN	death
in	IN	in
the	DT	the
first	JJ	first
year	NN	year
of	IN	of
life	NN	life
.	SENT	.
Since	IN	since
2006	CD	@card@
,	,	,
following	VVG	follow
the	DT	the
use	NN	use
of	IN	of
Alglucosidase	NN	Alglucosidase
alfa	NN	alfa
as	IN	as
Enzyme	NP	Enzyme
Replacement	NP	Replacement
Therapy	NP	Therapy
(	(	(
ERT	NN	ERT
)	)	)
,	,	,
the	DT	the
patients	NNS	patient
survival	NN	survival
is	VBZ	be
improved	VVN	improve
to	TO	to
a	DT	a
noticeable	JJ	noticeable
extent.The	NN	extent.The
purpose	NN	purpose
of	IN	of
this	DT	this
study	NN	study
is	VBZ	be
to	TO	to
examine	VV	examine
the	DT	the
outcome	NN	outcome
of	IN	of
IOPD	JJ	IOPD
patients	NNS	patient
in	IN	in
South	NP	South
of	IN	of
Iran	NP	Iran
and	CC	and
the	DT	the
degree	NN	degree
of	IN	of
responsiveness	NN	responsiveness
to	TO	to
ERT.All	NP	ERT.All
patients	NNS	patient
who	WP	who
were	VBD	be
diagnosed	VVN	diagnose
with	IN	with
IOPD	NN	IOPD
on	IN	on
the	DT	the
bases	NNS	base
of	IN	of
clinical	JJ	clinical
symptoms	NNS	symptom
,	,	,
and	CC	and
enzyme	NN	enzyme
assay	NN	assay
on	IN	on
dried	VVN	dry
blood	NN	blood
spot	NN	spot
,	,	,
were	VBD	be
included	VVN	include
in	IN	in
the	DT	the
study	NN	study
;	:	;
and	CC	and
were	VBD	be
followed	VVN	follow
up	IN	up
regarding	VVG	regard
cardiac	JJ	cardiac
function	NN	function
,	,	,
locomotor	JJ	locomotor
activity	NN	activity
,	,	,
and	CC	and
cognition.Six	NN	cognition.Six
patients	NNS	patient
with	IN	with
IOPD	NN	IOPD
were	VBD	be
identified	VVN	identify
.	SENT	.
All	PDT	All
these	DT	these
six	CD	six
patients	NNS	patient
suffered	VVN	suffer
from	IN	from
Hypertrophic	NP	Hypertrophic
Cardiomyopathy	NP	Cardiomyopathy
(	(	(
HCM	NP	HCM
)	)	)
.	SENT	.
Four	CD	Four
(	(	(
67	CD	@card@
%	NN	%
)	)	)
of	IN	of
them	PP	them
also	RB	also
had	VHD	have
generalized	VVN	generalize
hypotonia	NN	hypotonia
.	SENT	.
Three	CD	Three
patients	NNS	patient
expired	VVN	expire
during	IN	during
the	DT	the
first	JJ	first
weeks	NNS	week
due	JJ	due
to	TO	to
severe	JJ	severe
respiratory	JJ	respiratory
infection	NN	infection
.	SENT	.
One	CD	One
of	IN	of
them	PP	them
also	RB	also
got	VVD	get
involved	VVN	involve
with	IN	with
Acute	NP	Acute
Cardiopulmonary	NP	Cardiopulmonary
Failure	NN	failure
while	IN	while
receiving	VVG	receive
the	DT	the
fifth	JJ	fifth
dose	NN	dose
of	IN	of
ERT	NN	ERT
;	:	;
and	CC	and
expired	VVD	expire
.	SENT	.
However	RB	however
,	,	,
the	DT	the
remaining	VVG	remain
two	CD	two
patients	NNS	patient
had	VHD	have
a	DT	a
significant	JJ	significant
improvement	NN	improvement
after	IN	after
the	DT	the
maximum	NN	maximum
of	IN	of
117	CD	@card@
weeks	NNS	week
of	IN	of
following	VVG	follow
up	RP	up
both	DT	both
cardiac	JJ	cardiac
and	CC	and
locomotor	JJ	locomotor
findings	NNS	finding
.	SENT	.
These	DT	these
two	CD	two
patients	NNS	patient
were	VBD	be
the	DT	the
same	JJ	same
patients	NNS	patient
who	WP	who
showed	VVD	show
cardiac	JJ	cardiac
symptoms	NNS	symptom
from	IN	from
the	DT	the
beginning	NN	beginning
but	CC	but
did	VVD	do
not	RB	not
have	VH	have
generalized	VVN	generalize
hypotonia.Although	JJ	hypotonia.Although
ERT	NN	ERT
has	VHZ	have
a	DT	a
significant	JJ	significant
effect	NN	effect
on	IN	on
enhancing	VVG	enhance
the	DT	the
survival	NN	survival
of	IN	of
IOPD	JJ	IOPD
patients	NNS	patient
,	,	,
it	PP	it
should	MD	should
be	VB	be
associated	VVN	associate
with	IN	with
meticulous	JJ	meticulous
heart-respiratory	NN	heart-respiratory
cares	VVZ	care
during	IN	during
the	DT	the
first	JJ	first
months	NNS	month
of	IN	of
treatment	NN	treatment
and	CC	and
preventing	VVG	prevent
infection	NN	infection
especially	RB	especially
nosocomial	JJ	nosocomial
infections	NNS	infection
.	SENT	.



Pompe	NN	Pompe
disease	NN	disease
is	VBZ	be
a	DT	a
rare	JJ	rare
metabolic	JJ	metabolic
disorder	NN	disorder
due	JJ	due
to	TO	to
lysosomal	JJ	lysosomal
alpha-glucosidase	NN	alpha-glucosidase
(	(	(
GAA	NP	GAA
)	)	)
deficiency	NN	deficiency
.	SENT	.
It	PP	it
is	VBZ	be
considered	VVN	consider
as	IN	as
a	DT	a
multi-systemic	JJ	multi-systemic
disease	NN	disease
since	IN	since
,	,	,
although	IN	although
glycogen	NN	glycogen
accumulation	NN	accumulation
is	VBZ	be
largely	RB	largely
prominent	JJ	prominent
in	IN	in
heart	NN	heart
,	,	,
skeletal	JJ	skeletal
and	CC	and
respiratory	JJ	respiratory
muscles	NNS	muscle
,	,	,
other	JJ	other
organs	NNS	organ
can	MD	can
also	RB	also
be	VB	be
affected	VVN	affect
.	SENT	.
As	RB	as
regards	VVZ	regard
the	DT	the
vascular	JJ	vascular
system	NN	system
,	,	,
few	JJ	few
reports	NNS	report
have	VHP	have
documented	VVN	document
cerebrovascular	JJ	cerebrovascular
malformations	NNS	malformation
in	IN	in
Pompe	NP	Pompe
patients	NNS	patient
.	SENT	.
The	DT	the
aim	NN	aim
of	IN	of
this	DT	this
study	NN	study
was	VBD	be
to	TO	to
define	VV	define
the	DT	the
presence	NN	presence
and	CC	and
type	NN	type
of	IN	of
intracranial	JJ	intracranial
arterial	JJ	arterial
abnormalities	NNS	abnormality
in	IN	in
a	DT	a
cohort	NN	cohort
of	IN	of
late	JJ	late
onset	NN	onset
Pompe	NN	Pompe
disease	NN	disease
(	(	(
LOPD	NP	LOPD
)	)	)
patients.We	NP	patients.We
have	VHP	have
studied	VVN	study
21	CD	@card@
LOPD	JJ	LOPD
patients	NNS	patient
with	IN	with
cerebral	JJ	cerebral
CT	NP	CT
angiography	NN	angiography
(	(	(
CTA	NP	CTA
)	)	)
,	,	,
using	VVG	use
maximum	JJ	maximum
intensity	NN	intensity
projection	NN	projection
and	CC	and
volume	NN	volume
rendering	NN	rendering
technique	NN	technique
for	IN	for
3D-image	JJ	3D-image
reconstruction.We	NNS	reconstruction.We
found	VVD	find
intracranial	JJ	intracranial
arterial	JJ	arterial
abnormalities	NNS	abnormality
in	IN	in
13/21	CD	@card@
patients	NNS	patient
(	(	(
62	CD	@card@
%	NN	%
)	)	)
,	,	,
of	IN	of
whom	WP	whom
:	:	:
2/21	CD	@card@
patients	NNS	patient
(	(	(
9.5	CD	@card@
%	NN	%
)	)	)
showed	VVD	show
an	DT	an
unruptured	JJ	unruptured
intracranial	JJ	intracranial
aneurysm	NN	aneurysm
(	(	(
respectively	RB	respectively
2	CD	2
and	CC	and
4	CD	4
mm	NNS	mm
)	)	)
,	,	,
10/21	CD	@card@
(	(	(
47	CD	@card@
%	NN	%
)	)	)
had	VHD	have
a	DT	a
vertebrobasilar	JJ	vertebrobasilar
dolichoectasia	NN	dolichoectasia
(	(	(
VBD	NP	VBD
)	)	)
and	CC	and
1/21	CD	@card@
a	DT	a
basilar	JJ	basilar
artery	NN	artery
fenestration	NN	fenestration
.	SENT	.
Signs	NNS	sign
of	IN	of
lacunar	JJ	lacunar
encephalopathy	NN	encephalopathy
(	(	(
insular	JJ	insular
,	,	,
capsular	JJ	capsular
and	CC	and
frontal	JJ	frontal
subcortical	JJ	subcortical
lesions	NNS	lesion
)	)	)
were	VBD	be
detected	VVN	detect
in	IN	in
13/21	CD	@card@
patients	NNS	patient
(	(	(
62	CD	@card@
%	NN	%
)	)	)
and	CC	and
this	DT	this
correlated	VVN	correlate
with	IN	with
the	DT	the
presence	NN	presence
of	IN	of
respiratory	JJ	respiratory
impairment	NN	impairment
(	(	(
p 	JJ	p 
;	:	;
= 	NN	= 
;	:	;
0.017).These	JJ	0.017).These
findings	NNS	finding
differ	VVP	differ
from	IN	from
what	WP	what
has	VHZ	have
been	VBN	be
previously	RB	previously
observed	VVN	observe
in	IN	in
healthy	JJ	healthy
,	,	,
aged-matched	JJ	aged-matched
populations	NNS	population
and	CC	and
confirm	VVP	confirm
that	IN/that	that
cerebral	JJ	cerebral
arteries	NNS	artery
abnormalities	NNS	abnormality
,	,	,
mainly	RB	mainly
involving	VVG	involve
the	DT	the
posterior	JJ	posterior
circle	NN	circle
,	,	,
are	VBP	be
not	RB	not
so	RB	so
rare	JJ	rare
in	IN	in
LOPD	JJ	LOPD
patients	NNS	patient
and	CC	and
are	VBP	be
often	RB	often
accompanied	VVN	accompany
by	IN	by
a	DT	a
lacunar	JJ	lacunar
encephalopathy	NN	encephalopathy
that	WDT	that
might	MD	might
represent	VV	represent
a	DT	a
hypoxic-ischemic	JJ	hypoxic-ischemic
origin	NN	origin
.	SENT	.
A	DT	a
CTA	NP	CTA
or	CC	or
an	DT	an
MRA	NP	MRA
is	VBZ	be
recommended	VVN	recommend
,	,	,
in	IN	in
LOPD	JJ	LOPD
patients	NNS	patient
,	,	,
for	IN	for
early	JJ	early
detection	NN	detection
of	IN	of
cerebrovascular	JJ	cerebrovascular
malformations	NNS	malformation
as	IN	as
they	PP	they
could	MD	could
lead	VV	lead
to	TO	to
life-threatening	JJ	life-threatening
events	NNS	event
such	JJ	such
as	IN	as
sub-arachnoid	NN	sub-arachnoid
haemorrhage	NN	haemorrhage
or	CC	or
brainstem	NN	brainstem
compression	NN	compression
.	SENT	.



Phelan-McDermid	NP	Phelan-McDermid
NP	NP	NP
Phelan-McDermid	NP	Phelan-McDermid
syndrome	NN	syndrome
NN	NP	NN
syndrome	NN	syndrome
(	(	(
(	(	(
(	(	(
PMS	NP	PMS
NP	NP	NP
PMS	NP	PMS
)	)	)
)	)	)
)	)	)
or	CC	or
CC	NP	CC
or	CC	or
22q13.3	JJ	22q13.3
JJ	NN	JJ
22q13.3	JJ	22q13.3
deletion	NN	deletion
NN	NP	NN
deletion	NN	deletion
syndrome	NN	syndrome
NN	NP	NN
syndrome	NN	syndrome
is	VBZ	be
VBZ	NP	VBZ
be	VB	be
characterized	VVN	characterize
VVN	NP	VVN
characterize	VVP	characterize
by	IN	by
IN	IN	in
by	IN	by
a	DT	a
DT	NP	DT
a	DT	a
variable	JJ	variable
JJ	NN	JJ
variable	NN	variable
degree	NN	degree
NN	NP	NN
degree	NN	degree
of	IN	of
IN	IN	in
of	IN	of
intellectual	JJ	intellectual
JJ	NN	JJ
intellectual	JJ	intellectual
disability	NN	disability
NN	NP	NN
disability	NN	disability
,	,	,
,	,	,
,	,	,
impaired	JJ	impaired
VVN	NP	VVN
impair	VV	impair
speech	NN	speech
NN	NP	NN
speech	NN	speech
and	CC	and
CC	NP	CC
and	CC	and
language	NN	language
NN	NP	NN
language	NN	language
as	IN	as
RB	NN	RB
as	IN	as
well	RB	well
RB	NN	RB
well	RB	well
as	RB	as
IN	IN	in
as	IN	as
social	JJ	social
JJ	NN	JJ
social	JJ	social
communicative	JJ	communicative
JJ	NN	JJ
communicative	JJ	communicative
skills	NNS	skill
NNS	NP	NNS
skill	NN	skill
and	CC	and
CC	NP	CC
and	CC	and
mild	JJ	mild
JJ	NN	JJ
mild	JJ	mild
dysmorphic	JJ	dysmorphic
JJ	NN	JJ
dysmorphic	NN	dysmorphic
features	VVZ	feature
NNS	NP	NNS
feature	NN	feature
.	SENT	.
SENT	VVN	send
.	SENT	.
The	DT	the
DT	NP	DT
the	DT	the
SHANK3	NP	SHANK3
NP	NP	NP
SHANK3	NP	SHANK3
gene	NN	gene
NN	NP	NN
gene	NN	gene
is	VBZ	be
VBZ	NP	VBZ
be	VB	be
thought	VVN	think
VVN	NP	VVN
think	VVP	think
to	TO	to
TO	TO	TO
to	TO	to
be	VB	be
VB	NP	VB
be	VB	be
a	DT	a
DT	NP	DT
a	DT	a
major	JJ	major
JJ	NN	JJ
major	JJ	major
contributor	NN	contributor
NN	NP	NN
contributor	NN	contributor
to	TO	to
TO	TO	TO
to	TO	to
the	DT	the
DT	NP	DT
the	DT	the
phenotype	NN	phenotype
NN	NP	NN
phenotype	NN	phenotype
.	SENT	.
SENT	VVN	send
.	SENT	.
Apart	RB	apart
RB	NN	RB
apart	RB	apart
from	IN	from
IN	IN	in
from	IN	from
the	DT	the
DT	NP	DT
the	DT	the
syndrome-associated	JJ	syndrome-associated
JJ	NN	JJ
syndrome-associated	JJ	syndrome-associated
autistic	JJ	autistic
JJ	NN	JJ
autistic	JJ	autistic
features	NNS	feature
NNS	NNS	NNS
feature	VVP	feature
,	,	,
,	,	,
,	,	,
symptoms	NNS	symptom
NNS	NP	NNS
symptom	NN	symptom
from	IN	from
IN	IN	in
from	IN	from
the	DT	the
DT	NP	DT
the	DT	the
bipolar	JJ	bipolar
JJ	NN	JJ
bipolar	JJ	bipolar
spectrum	NN	spectrum
NN	NP	NN
spectrum	NN	spectrum
can	MD	can
MD	NNS	MD
can	MD	can
be	VB	be
VB	NP	VB
be	VB	be
discerned	VVN	discern
VVN	NP	VVN
discern	VV	discern
,	,	,
,	,	,
,	,	,
in	IN	in
IN	IN	in
in	IN	in
particular	JJ	particular
JJ	NN	JJ
particular	JJ	particular
behavior	NN	behavior
NN	NP	NN
behavior	NN	behavior
instability	NN	instability
NN	NP	NN
instability	NN	instability
and	CC	and
CC	NP	CC
and	CC	and
fluctuating	VVG	fluctuate
VVG	NP	VVG
fluctuate	VVP	fluctuate
mood	NN	mood
NN	NP	NN
mood	NN	mood
culminating	VVG	culminate
VVG	NP	VVG
culminate	VV	culminate
in	RP	in
IN	IN	in
in	IN	in
a	DT	a
DT	NP	DT
a	DT	a
(	(	(
(	(	(
(	(	(
hypo)manic	JJ	hypo)manic
JJ	NN	JJ
hypo)manic	JJ	hypo)manic
state	NN	state
NN	NP	NN
state	NN	state
.	SENT	.
SENT	VVN	send
.	SENT	.
In	IN	in
IN	IN	in
in	IN	in
case	NN	case
NN	NP	NN
case	NN	case
of	IN	of
IN	IN	in
of	IN	of
coincident	JJ	coincident
JJ	NN	JJ
coincident	JJ	coincident
major	JJ	major
JJ	NN	JJ
major	JJ	major
somatic	JJ	somatic
JJ	NN	JJ
somatic	JJ	somatic
events	NNS	event
NNS	NP	NNS
event	NN	event
,	,	,
,	,	,
,	,	,
a	DT	a
DT	NP	DT
a	DT	a
deteriorating	VVG	deteriorate
VVG	NP	VVG
deteriorate	VV	deteriorate
course	NN	course
NN	NP	NN
course	NN	course
may	MD	may
MD	NNS	MD
may	MD	may
occur	VV	occur
VV	NP	VV
occur	VV	occur
.	SENT	.
SENT	VVN	send
.	SENT	.
This	DT	this
DT	NP	DT
this	DT	this
study	NN	study
NN	NP	NN
study	NN	study
comprises	VVZ	comprise
VVZ	NP	VVZ
comprise	VV	comprise
seven	CD	seven
CD	NN	CD
seven	CD	seven
adult	NN	adult
NN	NP	NN
adult	NN	adult
patients	NNS	patient
NNS	NP	NNS
patient	NN	patient
(	(	(
(	(	(
(	(	(
four	CD	four
CD	NN	CD
four	CD	four
females	NNS	female
NNS	NP	NNS
female	NN	female
and	CC	and
CC	NP	CC
and	CC	and
three	CD	three
CD	NN	CD
three	CD	three
males	NNS	male
NNS	NP	NNS
male	NN	male
;	:	;
:	:	:
;	:	;
aged	VVN	age
VVN	NP	VVN
age	NN	age
21-44	CD	@card@
CD	NN	CD
@card@	NN	@card@
years	NNS	year
NNS	NP	NNS
year	NN	year
)	)	)
)	)	)
)	)	)
with	IN	with
IN	IN	in
with	IN	with
genetically	RB	genetically
RB	NN	RB
genetically	RB	genetically
proven	JJ	proven
VVN	NP	VVN
prove	VV	prove
PMS	NP	PMS
NP	NP	NP
PMS	NP	PMS
.	SENT	.
SENT	VVD	send
.	SENT	.
Data	NP	Data
NNS	NP	NNS
datum	NN	datum
from	IN	from
IN	IN	in
from	IN	from
medical	JJ	medical
JJ	NN	JJ
medical	JJ	medical
records	NNS	record
NNS	NP	NNS
record	NN	record
were	VBD	be
VBD	NP	VBD
be	VB	be
collected	VVN	collect
VVN	NP	VVN
collect	VVP	collect
and	CC	and
CC	NP	CC
and	CC	and
extensive	JJ	extensive
JJ	NN	JJ
extensive	JJ	extensive
assessment	NN	assessment
NN	NP	NN
assessment	NN	assessment
of	IN	of
IN	IN	in
of	IN	of
neuropsychological	JJ	neuropsychological
JJ	NN	JJ
neuropsychological	JJ	neuropsychological
variables	NNS	variable
NNS	NP	NNS
variable	NN	variable
was	VBD	be
VBD	NP	VBD
be	VB	be
performed	VVN	perform
VVN	NP	VVN
perform	VVP	perform
to	TO	to
TO	TO	TO
to	TO	to
identify	VV	identify
VV	NP	VV
identify	VV	identify
cognitive	JJ	cognitive
JJ	NN	JJ
cognitive	JJ	cognitive
characteristics	NNS	characteristic
NNS	NP	NNS
characteristic	NN	characteristic
and	CC	and
CC	NP	CC
and	CC	and
their	PP$	their
PP$	NP	PP$
their	PP$	their
relation	NN	relation
NN	NP	NN
relation	NN	relation
with	IN	with
IN	IN	in
with	IN	with
psychopathology	NN	psychopathology
NN	NP	NN
psychopathology	NN	psychopathology
and	CC	and
CC	NP	CC
and	CC	and
treatment	NN	treatment
NN	NP	NN
treatment	NN	treatment
.	SENT	.
SENT	VVN	send
.	SENT	.
All	DT	all
DT	NP	DT
all	DT	all
patients	NNS	patient
NNS	NP	NNS
patient	NN	patient
showed	VVD	show
VVD	RB	VVD
show	VV	show
profound	JJ	profound
JJ	NN	JJ
profound	JJ	profound
communication	NN	communication
NN	NP	NN
communication	NN	communication
deficits	NNS	deficit
NNS	NP	NNS
deficit	NN	deficit
and	CC	and
CC	NP	CC
and	CC	and
their	PP$	their
PP$	NP	PP$
their	PP$	their
developmental	JJ	developmental
JJ	NN	JJ
developmental	JJ	developmental
functioning	VVG	function
NN	NP	NN
functioning	NN	functioning
ranged	VVD	range
VVN	NP	VVN
range	NN	range
from	IN	from
IN	IN	in
from	IN	from
1.0	CD	@card@
CD	NN	CD
@card@	NN	@card@
to	TO	to
TO	TO	TO
to	TO	to
6.3	CD	@card@
CD	NN	CD
@card@	NN	@card@
years	NNS	year
NNS	NP	NNS
year	NN	year
.	SENT	.
SENT	VVN	send
.	SENT	.
In	IN	in
IN	IN	in
in	IN	in
addition	NN	addition
NN	NP	NN
addition	NN	addition
,	,	,
,	,	,
,	,	,
they	PP	they
PP	NP	PP
they	PP	they
had	VHD	have
VHD	NNS	VHD
have	VHP	have
slow	JJ	slow
JJ	NN	JJ
slow	JJ	slow
speed	NN	speed
NN	NP	NN
speed	NN	speed
of	IN	of
IN	IN	in
of	IN	of
information	NN	information
NN	NP	NN
information	NN	information
processing	NN	processing
NN	NP	NN
processing	NN	processing
,	,	,
,	,	,
,	,	,
impairment	NN	impairment
NN	NP	NN
impairment	NN	impairment
of	IN	of
IN	IN	in
of	IN	of
attentional	JJ	attentional
JJ	NN	JJ
attentional	NN	attentional
and	CC	and
CC	NP	CC
and	CC	and
executive	JJ	executive
JJ	NN	JJ
executive	NN	executive
functions	NNS	function
NNS	NP	NNS
function	NN	function
and	CC	and
CC	NP	CC
and	CC	and
cognitive	JJ	cognitive
JJ	NN	JJ
cognitive	JJ	cognitive
alexithymia	NN	alexithymia
NN	NP	NN
alexithymia	NN	alexithymia
.	SENT	.
SENT	VVN	send
.	SENT	.
As	IN	as
RB	NN	RB
as	IN	as
to	TO	to
TO	TO	TO
to	TO	to
psychopathology	NN	psychopathology
NN	NP	NN
psychopathology	NN	psychopathology
,	,	,
,	,	,
,	,	,
features	VVZ	feature
NNS	NP	NNS
feature	NN	feature
from	IN	from
IN	IN	in
from	IN	from
the	DT	the
DT	NP	DT
the	DT	the
affective	JJ	affective
NN	NP	NN
affective	NN	affective
and	CC	and
CC	NP	CC
and	CC	and
anxiety	NN	anxiety
NN	NP	NN
anxiety	NN	anxiety
domains	NNS	domain
NNS	NP	NNS
domain	NN	domain
were	VBD	be
VBD	NP	VBD
be	VB	be
prominent	JJ	prominent
JJ	NN	JJ
prominent	JJ	prominent
findings	NNS	finding
NNS	NP	NNS
finding	VVG	find
in	RP	in
IN	IN	in
in	IN	in
these	DT	these
DT	NP	DT
these	DT	these
seven	CD	seven
CD	NN	CD
seven	CD	seven
patients	NNS	patient
NNS	NP	NNS
patient	NN	patient
suggesting	VVG	suggest
VVG	NP	VVG
suggest	VVP	suggest
the	DT	the
DT	NP	DT
the	DT	the
presence	NN	presence
NN	NP	NN
presence	NN	presence
of	IN	of
IN	IN	in
of	IN	of
a	DT	a
DT	NP	DT
a	DT	a
bipolar	JJ	bipolar
JJ	NN	JJ
bipolar	JJ	bipolar
spectrum	NN	spectrum
NN	NP	NN
spectrum	NN	spectrum
disorder	NN	disorder
NN	NP	NN
disorder	NN	disorder
that	IN/that	that
WDT	NP	WDT
that	WDT	that
could	MD	could
MD	NNS	MD
could	MD	could
be	VB	be
VB	NP	VB
be	VB	be
effectively	RB	effectively
RB	NN	RB
effectively	RB	effectively
moderated	VVN	moderate
VVN	NP	VVN
moderate	JJ	moderate
with	IN	with
IN	IN	in
with	IN	with
mood-stabilizing	VVG	mood-stabilizing
VVG	NP	VVG
mood-stabilizing	VVG	mood-stabilizing
agents	NNS	agent
NNS	NP	NNS
agent	NN	agent
.	SENT	.
SENT	VVD	send
.	SENT	.
Results	NNS	result
NNS	NP	NNS
result	NN	result
are	VBP	be
VBP	NP	VBP
be	VB	be
discussed	VVN	discuss
VVN	NP	VVN
discuss	VV	discuss
in	RP	in
IN	IN	in
in	IN	in
terms	NNS	term
NNS	NP	NNS
term	NN	term
of	IN	of
IN	IN	in
of	IN	of
the	DT	the
DT	NP	DT
the	DT	the
putative	JJ	putative
JJ	NN	JJ
putative	JJ	putative
involvement	NN	involvement
NN	NP	NN
involvement	NN	involvement
of	IN	of
IN	IN	in
of	IN	of
structural	JJ	structural
JJ	NN	JJ
structural	JJ	structural
brain	NN	brain
NN	NP	NN
brain	NN	brain
abnormalities	NNS	abnormality
NNS	NP	NNS
abnormality	NN	abnormality
,	,	,
,	,	,
,	,	,
in	IN	in
IN	IN	in
in	IN	in
particular	JJ	particular
JJ	NN	JJ
particular	JJ	particular
cerebellar	JJ	cerebellar
JJ	NN	JJ
cerebellar	JJ	cerebellar
vermis	NN	vermis
NN	NP	NN
vermis	NN	vermis
hypoplasia	NN	hypoplasia
NN	NP	NN
hypoplasia	NN	hypoplasia
and	CC	and
CC	NP	CC
and	CC	and
corpus	NN	corpus
NN	NP	NN
corpus	NN	corpus
callosum	NN	callosum
NN	NP	NN
callosum	NN	callosum
thinning	VVG	thin
VVG	NP	VVG
thin	JJ	thin
and	CC	and
CC	NP	CC
and	CC	and
their	PP$	their
PP$	NP	PP$
their	PP$	their
cognitive	JJ	cognitive
JJ	NN	JJ
cognitive	JJ	cognitive
and	CC	and
CC	NP	CC
and	CC	and
emotional	JJ	emotional
JJ	NN	JJ
emotional	JJ	emotional
sequelae	NNS	sequela
NNS	NP	NNS
sequela	NN	sequela
.	SENT	.
SENT	VVN	send
.	SENT	.
It	PP	it
PP	NP	PP
it	PP	it
is	VBZ	be
VBZ	NP	VBZ
be	VB	be
concluded	VVN	conclude
VVN	NP	VVN
conclude	VVP	conclude
that	IN/that	that
IN/that	NP	IN/that
that	IN/that	that
the	DT	the
DT	NP	DT
the	DT	the
treatment	NN	treatment
NN	NP	NN
treatment	NN	treatment
of	IN	of
IN	IN	in
of	IN	of
22q13.3-associated	JJ	22q13.3-associated
JJ	NN	JJ
22q13.3-associated	JJ	22q13.3-associated
psychopathology	NN	psychopathology
NN	NP	NN
psychopathology	NN	psychopathology
should	MD	should
MD	NNS	MD
should	MD	should
include	VV	include
VV	NP	VV
include	VV	include
prescription	NN	prescription
NN	NP	NN
prescription	NN	prescription
of	IN	of
IN	IN	in
of	IN	of
mood-stabilizing	VVG	mood-stabilizing
VVG	NP	VVG
mood-stabilizing	VVG	mood-stabilizing
agents	NNS	agent
NNS	NP	NNS
agent	NN	agent
in	IN	in
IN	IN	in
in	IN	in
combination	NN	combination
NN	NP	NN
combination	NN	combination
with	IN	with
IN	IN	in
with	IN	with
individually	RB	individually
RB	NN	RB
individually	RB	individually
tailored	VVN	tailor
VVN	NP	VVN
tailor	NN	tailor
contextual	JJ	contextual
JJ	NN	JJ
contextual	JJ	contextual
neuropsychological	JJ	neuropsychological
JJ	NN	JJ
neuropsychological	NN	neuropsychological
measures	VVZ	measure
NNS	NP	NNS
measure	NN	measure
.	SENT	.
SENT	VVN	send
.	SENT	.



Late-onset	NN	late-onset
Pompe	NN	Pompe
disease	NN	disease
(	(	(
LOPD	NP	LOPD
)	)	)
is	VBZ	be
a	DT	a
rare	JJ	rare
treatable	JJ	treatable
lysosomal	JJ	lysosomal
storage	NN	storage
disorder	NN	disorder
characterized	VVN	characterize
by	IN	by
progressive	JJ	progressive
lysosomal	JJ	lysosomal
glycogen	NN	glycogen
accumulation	NN	accumulation
and	CC	and
muscle	NN	muscle
weakness	NN	weakness
,	,	,
with	IN	with
often	RB	often
a	DT	a
limb-girdle	NN	limb-girdle
pattern	NN	pattern
.	SENT	.
Despite	IN	despite
published	VVN	publish
guidelines	NNS	guideline
,	,	,
testing	VVG	test
for	IN	for
LOPD	NN	LOPD
is	VBZ	be
often	RB	often
overlooked	VVN	overlook
or	CC	or
delayed	VVN	delay
in	IN	in
adults	NNS	adult
,	,	,
owing	VVG	owe
to	TO	to
its	PP$	its
low	JJ	low
frequency	NN	frequency
compared	VVN	compare
to	TO	to
other	JJ	other
muscle	NN	muscle
disorders	NNS	disorder
with	IN	with
similar	JJ	similar
muscle	NN	muscle
patterns	NNS	pattern
.	SENT	.
Next-generation	NN	next-generation
sequencing	NP	sequencing
has	VHZ	have
the	DT	the
capability	NN	capability
to	TO	to
test	VV	test
concurrently	RB	concurrently
for	IN	for
several	JJ	several
muscle	NN	muscle
disorders	NNS	disorder
.	SENT	.
This	DT	this
could	MD	could
potentially	RB	potentially
lead	VV	lead
to	TO	to
increased	VVN	increase
diagnosis	NN	diagnosis
of	IN	of
LOPD	NP	LOPD
,	,	,
disorders	NNS	disorder
with	IN	with
non-specific	JJ	non-specific
muscle	NN	muscle
weakness	NN	weakness
or	CC	or
atypical	JJ	atypical
patients.We	NNS	patients.We
developed	VVD	develop
a	DT	a
gene	NN	gene
panel	NN	panel
to	TO	to
further	RBR	further
study	VV	study
its	PP$	its
clinical	JJ	clinical
utility	NN	utility
in	IN	in
a	DT	a
cohort	NN	cohort
of	IN	of
patients	NNS	patient
with	IN	with
suspected	JJ	suspected
muscle	NN	muscle
disorders	NNS	disorder
.	SENT	.
We	PP	we
designed	VVD	design
a	DT	a
gene	NN	gene
panel	NN	panel
to	TO	to
analyze	VV	analyze
the	DT	the
coding	VVG	code
sequences	NNS	sequence
and	CC	and
splice	VV	splice
site	NN	site
junctions	NNS	junction
of	IN	of
GAA	NP	GAA
causing	VVG	cause
LOPD	NN	LOPD
,	,	,
along	RB	along
with	IN	with
77	CD	@card@
other	JJ	other
genes	NNS	gene
causing	VVG	cause
muscle	NN	muscle
disorders	NNS	disorder
with	IN	with
overlapping	JJ	overlapping
phenotypes.At	NN	phenotypes.At
a	DT	a
median	JJ	median
coverage	NN	coverage
of	IN	of
~200X	NN	~200X
(	(	(
sequences	NNS	sequence
per	IN	per
base	NN	base
)	)	)
,	,	,
all	DT	all
GAA	NP	GAA
exons	NNS	exon
were	VBD	be
successfully	RB	successfully
covered	VVN	cover
with	IN	with
>20X	NN	>20X
and	CC	and
only	RB	only
0.3	CD	@card@
%	NN	%
of	IN	of
exons	NNS	exon
across	IN	across
all	DT	all
genes	NNS	gene
were	VBD	be
<20X	NN	<20X
.	SENT	.
The	DT	the
panel	NN	panel
showed	VVD	show
an	DT	an
excellent	JJ	excellent
sensitivity	NN	sensitivity
(	(	(
100	CD	@card@
%	NN	%
)	)	)
and	CC	and
specificity	NN	specificity
(	(	(
98	CD	@card@
%	NN	%
)	)	)
across	IN	across
all	DT	all
selected	JJ	selected
genes	NNS	gene
,	,	,
using	VVG	use
known	VVN	know
variations	NNS	variation
in	IN	in
Pompe	NP	Pompe
patients	NNS	patient
and	CC	and
controls	NNS	control
.	SENT	.
We	PP	we
determined	VVD	determine
its	PP$	its
clinical	JJ	clinical
utility	NN	utility
by	IN	by
analyzing	VVG	analyze
34	CD	@card@
patients	NNS	patient
with	IN	with
suspected	JJ	suspected
muscle	NN	muscle
disorders	NNS	disorder
of	IN	of
undetermined	JJ	undetermined
etiology	NN	etiology
and	CC	and
various	JJ	various
muscle	NN	muscle
patterns	NNS	pattern
,	,	,
who	WP	who
were	VBD	be
referred	VVN	refer
or	CC	or
followed	VVN	follow
in	IN	in
neuromuscular	JJ	neuromuscular
and	CC	and
genetics	NN	genetics
clinics	NNS	clinic
.	SENT	.
A	DT	a
putative	JJ	putative
diagnosis	NN	diagnosis
was	VBD	be
found	VVN	find
in	IN	in
up	IN	up
to	TO	to
32	CD	@card@
%	NN	%
of	IN	of
patients	NNS	patient
.	SENT	.
The	DT	the
gene	NN	gene
panel	NN	panel
was	VBD	be
instrumental	JJ	instrumental
in	IN	in
reaching	VVG	reach
a	DT	a
diagnosis	NN	diagnosis
in	IN	in
atypical	JJ	atypical
patients	NNS	patient
,	,	,
including	VVG	include
one	CD	one
LOPD	NN	LOPD
case	NN	case
.	SENT	.
Acid	JJ	acid
alpha-glucosidase	NN	alpha-glucosidase
activity	NN	activity
was	VBD	be
used	VVN	use
to	TO	to
confirm	VV	confirm
the	DT	the
molecular	JJ	molecular
results	NNS	result
in	IN	in
all	DT	all
patients.This	NN	patients.This
work	NN	work
highlights	VVZ	highlight
the	DT	the
high	JJ	high
clinical	JJ	clinical
utility	NN	utility
of	IN	of
gene	NN	gene
panels	NNS	panel
in	IN	in
patients	NNS	patient
with	IN	with
suspected	JJ	suspected
muscle	NN	muscle
disorders	NNS	disorder
and	CC	and
its	PP$	its
potential	NN	potential
to	TO	to
facilitate	VV	facilitate
the	DT	the
diagnosis	NN	diagnosis
of	IN	of
patients	NNS	patient
showing	VVG	show
non-specific	JJ	non-specific
muscle	NN	muscle
weakness	NN	weakness
or	CC	or
atypical	JJ	atypical
phenotypes	NNS	phenotype
.	SENT	.
We	PP	we
propose	VVP	propose
that	IN/that	that
gene	NN	gene
panels	NNS	panel
should	MD	should
be	VB	be
used	VVN	use
as	IN	as
a	DT	a
first-tier	NN	first-tier
test	NN	test
in	IN	in
patients	NNS	patient
with	IN	with
suspected	JJ	suspected
muscle	NN	muscle
disorders	NNS	disorder
of	IN	of
undetermined	JJ	undetermined
etiology	NN	etiology
,	,	,
which	WDT	which
could	MD	could
further	RBR	further
increase	VV	increase
overall	JJ	overall
diagnosis	NN	diagnosis
of	IN	of
muscle	NN	muscle
conditions	NNS	condition
,	,	,
and	CC	and
potentially	RB	potentially
reduce	VV	reduce
diagnostic	JJ	diagnostic
delay	NN	delay
.	SENT	.
Further	JJR	further
studies	NNS	study
are	VBP	be
necessary	JJ	necessary
to	TO	to
determine	VV	determine
the	DT	the
impact	NN	impact
of	IN	of
first-tier	NN	first-tier
gene	NN	gene
panels	NNS	panel
on	IN	on
diagnostic	JJ	diagnostic
delay	NN	delay
and	CC	and
on	IN	on
treatment	NN	treatment
outcome	NN	outcome
for	IN	for
LOPD	NP	LOPD
.	SENT	.







